
Amiloride
Description
Historical Context of Amiloride Discovery and Development
The discovery of this compound can be traced back to the late 1960s at Merck Sharp and Dohme Research Laboratories. It was identified during a screening program aimed at finding chemicals capable of reversing the in vivo effects of mineralocorticoids. This compound distinguished itself as the sole compound in this screen that promoted the excretion of sodium (natriuresis) without causing a simultaneous loss of potassium (kaliuresis) wikipedia.org. This selective action on sodium and potassium transport was a crucial finding that highlighted its potential as a potassium-sparing diuretic wikipedia.org.
The synthesis of this compound hydrochloride, a synthetic pyrazine derivative, stemmed from the observation in 1965 by Bickling and colleagues that certain nonsteroidal acylguanidine derivatives exhibited both natriuretic and antikaliuretic properties nih.gov. This compound was subsequently approved by the U.S. Food and Drug Administration (FDA) on October 5, 1981 wikipedia.org.
Evolution of this compound's Research Trajectory
Since its initial discovery, the research trajectory of this compound has evolved significantly. Thousands of this compound analogues have been synthesized and studied to further understand the effects of sodium transporters wikipedia.org. Early studies characterized this compound as an inhibitor of sodium-proton antiporter-dependent tumor growth and urokinase plasminogen activator-mediated metastasis biorxiv.org.
The primary mechanism of action identified is the direct blockade of the epithelial sodium channel (ENaC), with a reported IC50 around 0.1 μM, indicating potent inhibition wikipedia.org. This blockade inhibits sodium reabsorption in the late distal convoluted tubules, connecting tubules, and collecting ducts of the nephron, leading to increased sodium and water excretion while reducing potassium excretion wikipedia.orgpatsnap.com.
Beyond ENaC, research has revealed that this compound also inhibits other ion transporters, including the Na+/H+ exchanger (NHE) and the Na+/Ca2+ exchanger (NCX) at higher concentrations oup.comdroracle.ai. This compound and its derivatives have been particularly important tools for studying NHE-1, the ubiquitous isoform of the sodium/hydrogen exchanger protein family nih.gov. Studies have implicated specific residues in the transmembrane domains of NHE-1 in this compound binding nih.gov.
More recent research has explored this compound derivatives for their potential as selective cytotoxic agents towards tumor cells, acting via a non-apoptotic mechanism involving the lysosome biorxiv.org. Studies have also investigated this compound's potential in conditions like cystic fibrosis due to its ENaC inhibitory properties, which could potentially hydrate airway surfaces nih.gov. Research has also explored its effects on alternative splicing in cancer cells researchgate.net.
Significance of this compound as a Research Tool and Therapeutic Agent
This compound holds significant importance as both a research tool and a therapeutic agent. As a research tool, its relatively selective inhibition of ENaC, particularly at low concentrations, makes it invaluable for studying the role of these channels in various physiological processes oup.com. This compound and its analogues are widely used to investigate the function and characteristics of ENaC, NHE, and NCX proteins wikipedia.orgoup.comnih.gov.
As a therapeutic agent, this compound is primarily utilized as a potassium-sparing diuretic, often in combination with other diuretics like thiazides or loop diuretics, to manage conditions such as hypertension and edema associated with heart failure or cirrhosis of the liver wikipedia.orgnih.govpatsnap.com. Its ability to counteract the potassium-losing effects of other diuretics is a key clinical benefit wikipedia.orgnih.gov.
Research has demonstrated this compound's effectiveness in specific patient populations, such as those with Liddle phenotype, a genetic disorder characterized by upregulated ENaC activity wikipedia.org. In these cases, this compound's ENaC inhibition helps normalize blood pressure and electrolyte levels nih.gov. Studies have also shown that combining this compound with thiazide diuretics can have positive effects on blood pressure and blood sugar tolerance, potentially mitigating the metabolic side effects of thiazides wikipedia.org. Recent clinical trials have also investigated this compound's noninferiority compared to spironolactone in treating resistant hypertension acc.org.
Beyond its established uses, this compound and its derivatives are being investigated for potential therapeutic applications in other areas, including cystic fibrosis, lithium-induced polyuria, and certain cancers like multiple myeloma nih.govresearchgate.netaacrjournals.orgaacrjournals.org. Preclinical studies suggest this compound can induce apoptosis in multiple myeloma cell lines nih.gov.
The ongoing research into this compound and its analogues underscores its continued significance in understanding ion channel function and exploring new therapeutic possibilities.
Table: this compound Chemical Information
Compound Name | PubChem CID |
This compound | 16231 |
Table: Selected Research Findings Related to this compound's Mechanism
Target Protein/Channel | Mechanism of Action | Reported IC50/Effect | Research Context | Source |
Epithelial Sodium Channel (ENaC) | Direct blockade | ~0.1 μM (potent inhibition) wikipedia.org | Renal physiology, Diuretic action, Liddle syndrome | wikipedia.orgoup.comnih.gov |
Na+/H+ Exchanger (NHE) | Inhibition | Inhibited at higher doses droracle.ai | Ion transport studies, Cellular pH regulation | wikipedia.orgdroracle.ainih.gov |
Na+/Ca2+ Exchanger (NCX) | Weak reversible inhibition | IC50 = 2 mM latoxan.com | Ion transport studies | oup.comlatoxan.com |
Cyclic GMP-gated cation channels | Inhibition | Fraction of effects wikipedia.org | Renal physiology | wikipedia.org |
TRPP3, acid sensing- (ASIC), mechanogated membrane-ion channels | Blockade | Inhibited fishersci.ca | Ion channel research | fishersci.ca |
Urokinase-type plasminogen activator (uPA) | Inhibition | Inhibited fishersci.ca | Cancer research | biorxiv.orgfishersci.ca |
Table: this compound Physical and Chemical Properties (Selected)
Property | Value | Source |
Molecular Formula | C6H8ClN7O | wikipedia.orginchem.orgdrugbank.com |
Molar Mass | 229.63 g·mol−1 | wikipedia.org |
Appearance | Crystalline solid or very light yellow powder nih.gov, Yellow to greenish yellow solid-crystal inchem.org | inchem.orgnih.gov |
Melting Point | 240.5 to 241.5 °C (464.9 to 466.7 °F) | wikipedia.orginchem.org |
Solubility in water | 0.52 g/100 mL at 25°C inchem.org, less than 1 mg/mL at 67.1 °F nih.gov, Rarely soluble in water researchgate.net | inchem.orgnih.govresearchgate.net |
pKa | 8.7 inchem.orgresearchgate.net | inchem.orgresearchgate.net |
Properties
IUPAC Name |
3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide | |
---|---|---|
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI |
InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15) | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI Key |
XSDQTOBWRPYKKA-UHFFFAOYSA-N | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Canonical SMILES |
C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Molecular Formula |
C6H8ClN7O | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Related CAS |
17440-83-4 (hydrochloride), 2016-88-8 (anhydrous hydrochloride) | |
Record name | Amiloride [INN:BAN] | |
Source | ChemIDplus | |
URL | https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0002609463 | |
Description | ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system. | |
DSSTOX Substance ID |
DTXSID9043853 | |
Record name | Amiloride | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID9043853 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Molecular Weight |
229.63 g/mol | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Physical Description |
Solid | |
Record name | Amiloride | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014732 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Solubility |
Slightly soluble, 1.22e+00 g/L | |
Record name | Amiloride | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB00594 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Amiloride | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014732 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
CAS No. |
2609-46-3, 2016-88-8 | |
Record name | Amiloride | |
Source | CAS Common Chemistry | |
URL | https://commonchemistry.cas.org/detail?cas_rn=2609-46-3 | |
Description | CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society. | |
Explanation | The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. | |
Record name | Amiloride [INN:BAN] | |
Source | ChemIDplus | |
URL | https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0002609463 | |
Description | ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system. | |
Record name | Amiloride | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB00594 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Amiloride | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID9043853 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Record name | Amiloride | |
Source | European Chemicals Agency (ECHA) | |
URL | https://echa.europa.eu/substance-information/-/substanceinfo/100.018.205 | |
Description | The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness. | |
Explanation | Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page. | |
Record name | AMILORIDE | |
Source | FDA Global Substance Registration System (GSRS) | |
URL | https://gsrs.ncats.nih.gov/ginas/app/beta/substances/7DZO8EB0Z3 | |
Description | The FDA Global Substance Registration System (GSRS) enables the efficient and accurate exchange of information on what substances are in regulated products. Instead of relying on names, which vary across regulatory domains, countries, and regions, the GSRS knowledge base makes it possible for substances to be defined by standardized, scientific descriptions. | |
Explanation | Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. | |
Record name | Amiloride | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014732 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Melting Point |
240.5-241.5, 240 °C | |
Record name | Amiloride | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB00594 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Amiloride | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014732 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Pharmacological Profiles in Research Models
Absorption and Distribution Studies
Studies in research models and humans indicate that amiloride is absorbed following oral administration, although the absorption may be incomplete. Approximately 50% of an oral dose is absorbed hres.cahres.ca. Food can reduce the extent of absorption or bioavailability mims.com. Peak plasma concentrations are typically reached within 3 to 4 hours after oral administration hres.camims.comnih.gov.
This compound exhibits extravascular distribution and has a relatively high volume of distribution, reported to be between 350 and 380 L mims.comnih.gov. This high volume of distribution suggests that the compound distributes into tissues beyond the plasma compartment nih.gov. Plasma protein binding of this compound is reported to be approximately 23% ontosight.ai or less than 40% nih.gov. This compound is known to accumulate in certain tissues, including the kidneys, liver, and salivary glands, which aligns with its primary site of action in the kidneys ontosight.ai.
Intranasal administration of this compound has also been investigated in preclinical models and healthy human volunteers, showing rapid absorption into systemic circulation within 10 minutes eventscribe.netresearchgate.net. Intranasal administration can result in a biphasic pharmacokinetic profile, with an initial rapid absorption via the nasal pathway followed by slower absorption through non-nasal pathways researchgate.netresearchgate.net.
Metabolism and Elimination Pathways
A significant characteristic of this compound's metabolic profile is that it undergoes minimal hepatic metabolism hres.canih.govontosight.aiontosight.ai. The majority of the drug is excreted unchanged hres.canih.govontosight.aiontosight.aidrugbank.com.
The primary route of elimination for this compound is through the kidneys nih.govontosight.aiontosight.aidrugbank.com. Approximately 50% of an oral dose is excreted unchanged in the urine within 72 hours hres.canih.govdrugbank.com. The kidneys secrete this compound into the renal tubules, where it exerts its diuretic effect ontosight.ai.
In addition to renal excretion, a significant portion of this compound is eliminated via feces. Around 40% of an oral dose is excreted in the stool within 72 hours hres.canih.govdrugbank.com. This fecal excretion primarily represents unabsorbed drug emcrit.org.
The elimination half-life of this compound in individuals with normal kidney function typically ranges from 6 to 9 hours hres.camims.comnih.govontosight.aiontosight.aidrugbank.com. This relatively long half-life supports once-daily dosing in many cases ontosight.ai. In the context of renal impairment, the half-life can be significantly prolonged, ranging from 21 to 144 hours in patients with chronic kidney disease emcrit.orgoup.com.
Pharmacodynamic Research
Pharmacodynamic research explores how this compound interacts with biological targets and the resulting physiological effects. This compound is primarily known for its activity as a potassium-sparing diuretic.
Its main mechanism of action involves the inhibition of epithelial sodium channels (ENaC) nih.govontosight.aidrugbank.comwikipedia.org. This blockade occurs in the distal convoluted tubules and collecting ducts of the kidneys nih.govdrugbank.comwikipedia.org. By inhibiting ENaC, this compound reduces sodium reabsorption from the tubular lumen mims.comnih.govdrugbank.com. This decrease in sodium reabsorption leads to increased sodium and water excretion, contributing to a diuretic effect ontosight.ai. Crucially, the inhibition of ENaC also reduces the secretion of potassium and hydrogen ions, leading to potassium retention mims.comdrugbank.com. This compound's potassium-sparing effect is observed even in the absence of aldosterone, indicating a direct tubular action hres.cadrugbank.com.
Beyond its well-established renal effects, research models have explored other potential pharmacodynamic activities of this compound. Preclinical studies suggest that this compound may induce apoptosis in multiple myeloma cell lines nih.govaacrjournals.org. In vitro and ex vivo studies have shown potent activity against a broad panel of multiple myeloma cell lines aacrjournals.org. This compound has also demonstrated synergistic effects when combined with other agents like dexamethasone, melphalan, lenalidomide, and pomalidomide in multiple myeloma models aacrjournals.org. Investigations into the mechanisms underlying its anti-cancer effects are ongoing, with studies suggesting caspase-independent cytotoxicity in certain cancer cell lines plos.org.
This compound has also been investigated for its effects on acid-sensing ion channels (ASICs). Preclinical models indicate that this compound, as a nonselective antagonist of ASICs, can affect baroreflex sensitivity and blood pressure regulation physiology.org. Studies using intranasal this compound in preclinical anxiety models have shown efficacy in reducing anxious responses by inhibiting ASICs in the brain researchgate.netresearchgate.net.
Time-Action Profiles in Experimental Systems
The time-action profile of this compound has been characterized in experimental systems, primarily in the context of its diuretic effects. Following oral administration, the onset of diuretic action typically occurs within 1 to 2 hours hres.cahres.canih.gov. The effect on electrolyte excretion, specifically natriuresis and potassium retention, reaches a peak between 6 and 10 hours after administration hres.cahres.ca. The duration of the diuretic effect generally lasts for approximately 24 hours hres.camims.comnih.govwikipedia.org.
In studies evaluating intranasal administration, this compound has been detected in plasma rapidly, within 10 minutes eventscribe.netresearchgate.net. The plasma concentration profile can be biphasic, with an initial peak occurring shortly after administration (within 10 minutes) followed by a second peak several hours later (between 4-8 hours) researchgate.netresearchgate.net.
Dose-Response Relationships in Preclinical Models
Dose-response relationships for this compound have been established in various preclinical models, particularly concerning its effects on electrolyte excretion. In animal studies, a dose-response relationship has been demonstrated for the actions of this compound in reducing the fractional excretion of magnesium and potassium during furosemide-induced diuresis magnesium-ges.de. While this compound shows magnesium-sparing properties, its effects on magnesium excretion are less pronounced than those on potassium excretion magnesium-ges.de.
In rats, increasing the oral dose of this compound hydrochloride from 0.25 to 4.0 mg/kg results in only moderate increases in natriuresis, although this activity persists for over 6 hours hres.cahres.ca. When administered with other diuretics like chlorothiazide, hydrochlorothiazide, or acetazolamide in rats, this compound hydrochloride increases sodium excretion and antagonizes the kaliuretic effect of the other diuretic hres.cahres.ca. Studies in dogs using oral doses of 0.1 to 0.5 mg/kg of this compound hydrochloride increased sodium excretion and decreased potassium excretion when given with ethacrynic acid or hydrochlorothiazide hres.ca.
Research in multiple myeloma cell lines has shown that this compound induces significant apoptosis in a dose-dependent manner aacrjournals.org. For example, studies using H929, KMS12-BM, and JJN3 cell lines demonstrated increased apoptosis after 24 and 48 hours of incubation with increasing concentrations of this compound (0.1–1.0 mmol/L) aacrjournals.org.
In animal models of hypertension, doses of this compound ≤1 μmol/L have been shown to mitigate cardiovascular and renal disease progression oup.com. These effects occurred without changes in steady-state serum potassium levels oup.com. This compound inhibits ENaC much more efficiently than other ion channels at submicromolar concentrations (≤1 μmol/L), with an IC50 in the range of 0.1 to 0.5 μmol/L for ENaC oup.comwikipedia.org. Higher concentrations may affect other transporters like the Na+/H+ exchanger (NHE) and Na+/Ca2+ exchanger (NCX) oup.comwikipedia.orglatoxan.com.
Interactive Data Table Placeholder: Dose-Response on Electrolyte Excretion in Rats
This compound Oral Dose (mg/kg) | Effect on Natriuresis | Effect on Kaliuresis |
0.25 - 4.0 | Moderate increase | Decrease (when combined with other diuretics) |
Note: This table is a placeholder based on the description in the text. Actual interactive table functionality would require a specific platform.
Interactive Data Table Placeholder: this compound Effect on Multiple Myeloma Cell Apoptosis (Example Data)
Cell Line | This compound Concentration (mmol/L) | Apoptosis (%) at 24h | Apoptosis (%) at 48h |
H929 | 0.1 | Data from research | Data from research |
H929 | 0.5 | Data from research | Data from research |
H929 | 1.0 | Data from research | Data from research |
KMS12-BM | 0.1 | Data from research | Data from research |
KMS12-BM | 0.5 | Data from research | Data from research |
KMS12-BM | 1.0 | Data from research | Data from research |
JJN3 | 0.1 | Data from research | Data from research |
JJN3 | 0.5 | Data from research | Data from research |
JJN3 | 1.0 | Data from research | Data from research |
Note: This table is a placeholder. Actual interactive table functionality would require a specific platform and access to the specific data points from the cited research.
Preclinical Research and Therapeutic Potential
Renal Physiology and Disease Models
Amiloride's impact on renal function has been studied extensively in various preclinical models of kidney disease, focusing on its interaction with sodium channels and its influence on electrolyte balance and fluid handling.
Studies in Liddle Syndrome Models
Liddle syndrome is a genetic disorder characterized by hypertension, hypokalemia, and metabolic alkalosis, resulting from increased activity of the epithelial sodium channel (ENaC) in the distal nephron. researchgate.netdovepress.comnih.govtandfonline.comnih.gov Mutations in the genes encoding ENaC subunits lead to increased channel activity, often by impairing their degradation or increasing their open probability. researchgate.netdovepress.comnih.govnih.gov
Preclinical studies utilizing animal models of Liddle syndrome have demonstrated that this compound, as an ENaC blocker, can effectively reduce ENaC activity. researchgate.netdovepress.com In these models, this compound, often combined with a low-sodium diet, has been shown to help restore normotension and correct electrolyte imbalances. statpearls.comresearchgate.netdovepress.com Research using whole-cell patch-clamp recordings in microdissected nephron fragments from mice with Liddle syndrome mutations indicated that the primary site of increased Na+ reabsorption is the DCT2/CNT. ahajournals.orgnih.gov These studies measured this compound-sensitive ENaC currents and found enhanced ENaC activity, particularly in the DCT2/CNT, which contributes to sodium retention and hypertension observed in Liddle syndrome models. ahajournals.orgnih.gov Furthermore, studies have shown that in Liddle syndrome, the aldosterone responsiveness of ENaC is increased, rather than decreased. ahajournals.orgnih.gov In vitro studies using Chinese Hamster Ovary (CHO) cells expressing mutant ENaC subunits from Liddle syndrome patients have also shown higher this compound-sensitive currents compared to wild-type channels, confirming the enhanced ENaC activity and its inhibition by this compound. frontiersin.org
Research in Nephrotic Syndrome Models
Nephrotic syndrome is characterized by significant proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Edema formation in nephrotic syndrome is often linked to avid sodium retention in the kidneys. Preclinical studies in animal models of nephrotic syndrome have indicated that the epithelial sodium channel (ENaC) in the distal tubule is a site of sodium retention. emjreviews.comturkjnephrol.org Treatment with this compound, an ENaC blocker, has been shown to prevent volume retention in nephrotic rats and mice. emjreviews.comturkjnephrol.org This effect appears to be independent of aldosterone activity in experimental nephrotic syndrome. emjreviews.comturkjnephrol.org
Studies suggest that proteolytic activation of ENaC by proteases in the urine, resulting from aberrant glomerular filtration of plasminogen and its conversion to plasmin, may contribute to this compound-sensitive sodium retention in nephrotic syndrome. emjreviews.comturkjnephrol.orgfrontiersin.org Research in rats with induced nephrotic syndrome found higher levels of urinary plasminogen activator, and this compound treatment reduced this activity and sodium retention without altering proteinuria. frontiersin.org In animal models, this compound successfully abolishes abnormally high sodium reabsorption from the cortical collecting duct, independent of aldosterone activity. frontiersin.org
Investigations in Renal Tubular Acidosis Models
Renal Tubular Acidosis (RTA) is a group of disorders where the kidneys fail to excrete hydrogen ions or reabsorb bicarbonate properly, leading to metabolic acidosis. msdmanuals.com While the primary treatment for RTA involves alkali therapy, preclinical observations and case reports have explored the role of this compound in specific contexts. A case report described the use of this compound for the treatment of severe refractory symptomatic hypokalemia associated with type 1 renal tubular acidosis. nih.govstatpearls.com This suggests a potential role for this compound in managing electrolyte imbalances in certain forms of RTA, likely due to its potassium-sparing effects via ENaC inhibition, which reduces potassium secretion. nih.govmdpi.com
Preclinical studies have also investigated this compound's effects in models of lithium-induced kidney damage, which can lead to nephrogenic diabetes insipidus and interstitial fibrosis. otago.ac.nz In an established model of long-term lithium-induced interstitial fibrosis in rats, delayed co-administration with this compound reduced the progression of fibrosis. otago.ac.nz Further research in this model suggested that this compound attenuates pro-inflammatory pathways induced by lithium, including NF-κB and activated Akt, and increases anti-inflammatory pathways. otago.ac.nz This indicates a potential anti-inflammatory and anti-fibrotic effect of this compound in the context of lithium-induced renal injury, which may be relevant to tubular disorders.
Modulation of Renal Uric Acid Excretion
Uric acid homeostasis is maintained by a balance between production and excretion, primarily by the kidneys. Renal handling of uric acid involves filtration, reabsorption, and secretion in the proximal tubule, mediated by various urate transporters. nih.govmdpi.comresearchgate.net
Prolonged use of this compound can reduce the excretion of renal uric acid. nih.govstatpearls.com This effect is thought to be related to volume contraction caused by its diuretic action, which can lead to increased reabsorption of uric acid from the proximal convoluted tubule. nih.govstatpearls.com Some studies suggest that the transport activity of certain organic anion transporters (OATs), like OAT4, which are involved in uric acid transport, may be coupled with the effect of NHE3. nih.gov this compound is known to inhibit NHE3 at higher concentrations, which could potentially influence the activity of transporters like OAT4, indirectly affecting uric acid handling. However, the primary mechanism for reduced uric acid excretion with prolonged this compound use appears to be related to volume status. nih.govstatpearls.com
Cardiovascular System Research
This compound's effects extend beyond the kidneys, with preclinical research exploring its potential in the cardiovascular system, particularly regarding its antihypertensive mechanisms.
Antihypertensive Mechanisms Beyond Diuresis
While this compound's diuretic action contributes to its antihypertensive effect, preclinical studies suggest additional mechanisms. This compound has the potential to cause vasodilation. nih.govstatpearls.com
Furthermore, the epithelial sodium channel (ENaC) is present and functional in non-renal epithelial cells, including those in the cardiovascular system such as endothelial cells, smooth muscle cells, and fibroblasts. oup.com Preclinical studies have shown that this compound can antagonize or prevent the actions of aldosterone in these non-renal tissues in animal models of salt-dependent hypertension. oup.com This suggests that ENaC inhibition in the cardiovascular system might contribute to this compound's antihypertensive effects, independent of its renal actions.
Research in experimental hypertension animal models has indicated that this compound can mitigate cardiovascular and renal disease progression even in the presence of elevated blood pressure. oup.com These benefits have been observed without significant changes in steady-state serum potassium levels in some studies. oup.com this compound's ability to prevent or mitigate cardiac fibrosis in experimental models has also been noted, with the postulated mechanism potentially related to the maintenance of myocardial potassium concentration. oup.com
Preclinical models also indicate that this compound, as a nonselective antagonist of acid-sensing ion channels (ASICs), may influence baroreflex sensitivity and blood pressure regulation. physiology.orgnih.gov However, studies translating these findings to humans have shown contrasting results, with a single oral dose of this compound not affecting spontaneous arterial baroreflex sensitivity and blood pressure variability in healthy young adults. physiology.orgnih.gov
In addition to direct vascular effects and non-renal ENaC inhibition, preclinical research suggests this compound may have anti-inflammatory effects relevant to cardiovascular health. Studies in angiotensin II-hypertensive mice with type 1 diabetes treated with this compound showed increased TNF in cardiac and kidney tissues. physiology.org However, in vitro studies using lipopolysaccharide-stimulated human macrophages demonstrated that this compound and benzamil (an this compound analog) decreased pro-inflammatory cytokines like TNF, IL-6, IL-10, and IL-1β. physiology.org This suggests a potential direct action of this compound on macrophages to reduce pro-inflammatory cytokine release, which could contribute to its cardiovascular benefits. physiology.org
Cardioprotective Effects
Preclinical investigations have explored the potential cardioprotective effects of this compound, particularly in the context of myocardial ischemia-reperfusion injury and cardiac remodeling. This compound, as an inhibitor of the Na+/H+ exchanger (NHE1), has shown promise in reducing intracellular sodium and consequently calcium accumulation, which are key factors in myocardial injury during ischemia-reperfusion. mdpi.comjacc.org Studies in isolated rat hearts subjected to ischemia/reperfusion demonstrated that this compound treatment significantly decreased the release of lactate dehydrogenase (LDH) and creatine kinase (CK), markers of cardiac damage, and reduced infarct size. nih.gov This suggests a protective effect against ischemia/reperfusion-induced injury.
Furthermore, research in animal models of hypertension and obesity has indicated that this compound may mitigate cardiovascular and renal disease progression and reduce vascular stiffness. oup.comresearchgate.net Inhibition of ENaC with this compound has been shown to decrease oxidative stress, endothelium permeability, inflammation, arterial fibrosis, and aortic stiffness in obese mice. researchgate.net These effects were observed even in the absence of changes in blood pressure or sodium retention in some studies. researchgate.net
However, the translation of these positive preclinical findings with NHE1 inhibitors, including this compound, into successful clinical outcomes for ischemic heart disease has faced challenges. mdpi.comjacc.org
Respiratory System Research
Cystic Fibrosis Research
This compound has been extensively investigated for its potential therapeutic use in Cystic Fibrosis (CF), a genetic disorder characterized by abnormal airway epithelial electrolyte transport leading to dehydrated airway surface liquid (ASL) and impaired mucociliary clearance. ersnet.orgatsjournals.organnualreviews.org The rationale for using this compound in CF is based on its ability to block the epithelial sodium channel (ENaC), which is hyperactive in CF airways, leading to excessive sodium and water absorption. ersnet.orgatsjournals.orgnih.govatsjournals.org By inhibiting ENaC, this compound is hypothesized to reduce excessive sodium and water absorption, thereby improving the hydration of the ASL and enhancing mucus clearance. ersnet.orgatsjournals.orgresearchgate.net
Studies have shown that application of this compound to CF airway epithelia in vitro reduces sodium absorption. ersnet.org In patients with CF, inhalation of a single dose of this compound has been shown to increase mucociliary clearance. ersnet.org
Despite the promising theoretical basis and initial positive findings, clinical trials with nebulized this compound in CF patients have yielded mixed results. Some early studies suggested a potential benefit, including a reduction in the rate of decline in forced vital capacity (FVC) and improvement in sputum rheological properties ersnet.orgnih.gov. However, other studies, including a randomized, double-blind, placebo-controlled, cross-over trial, did not find significant additional clinical benefit from nebulized this compound in patients receiving established CF treatment. ersnet.orgnih.gov
Data from a study comparing nebulized this compound and placebo over two six-month periods in CF patients indicated no significant changes in several parameters, as shown in the table below. ersnet.org
Parameter | This compound Treatment | Placebo Treatment | Statistical Significance (p-value) |
Forced Expiratory Volume (FEV1) | No significant change | No significant change | Not significantly different |
Forced Vital Capacity (FVC) | No significant change | No significant change | Not significantly different |
Oxygen Saturation | No significant change | No significant change | Not significantly different |
Body Weight | No significant change | No significant change | Not significantly different |
Sputum Volume | No significant change | No significant change | Not significantly different |
Sputum Rheology | No significant change | No significant change | Not significantly different |
Frequency of Exacerbations | No significant difference | No significant difference | Not significantly different |
The limited clinical efficacy of this compound in CF may be attributed to factors such as its relatively low potency and short duration of action on the airway surface, as well as rapid absorption from the mucosal surface. atsjournals.orgscilit.com
Impact on Airway Surface Liquid Hydration
In CF, increased sodium absorption across airway epithelia leads to increased osmotic water absorption, which is thought to reduce the hydration of the airway surface liquid (ASL). ersnet.orgresearchgate.net this compound, by blocking ENaC, is postulated to increase ASL volume by inhibiting sodium and fluid absorption. researchgate.net In vitro studies and research using animal models of CF lung disease have shown that inhibition of ENaC can restore ASL hydration. researchgate.net
However, studies investigating the direct impact of this compound inhalation on sputum water content in CF patients have not always shown a measurable change, suggesting that the mechanism for mucus improvement by this compound might be more complex than solely increasing bulk water content. atsjournals.org Despite this, the rationale remains that improving ASL hydration is a key therapeutic target in CF, and this compound's ability to block ENaC aligns with this goal. annualreviews.orgresearchgate.net
Effects on Mucus Rheology and Clearance
Abnormal mucus rheology and impaired mucociliary clearance are central features of CF lung disease. atsjournals.orgatsjournals.orgnih.gov The dehydration of the ASL in CF contributes to thickened mucus that is difficult to clear by ciliary action and coughing. annualreviews.orgnih.govatsjournals.org
This compound inhalation therapy has been hypothesized to improve the rheological properties of mucus, making it more amenable to clearance. atsjournals.org Some studies have reported that this compound treatment improved measured indexes of sputum viscosity and elasticity and enhanced calculated indexes of mucociliary and cough clearance in adult CF patients. nih.gov One study indicated that chronic this compound therapy increased sputum sodium and chloride content and decreased the principal index of sputum rigidity (log G*). atsjournals.org
Data from a study on this compound inhalation therapy in CF patients showed changes in sputum ion content and rheology: atsjournals.org
Parameter | Baseline (Saline Treatment) | Chronic this compound Therapy (25 weeks) | Acute this compound Treatment (after Chronic) |
Sputum Sodium (mmol/L) | 94.8 ± 16.4 | 121.4 ± 15.4 | Up to 143.3 ± 27.7 |
Sputum Chloride (mmol/L) | 64.4 ± 11.8 | 77.2 ± 8.0 | Up to 95.1 ± 11.5 |
Sputum Potassium (mmol/L) | Not altered | Not altered | Not altered |
Sputum Rigidity (log G*) | Abnormal | Decreased | Decreased further |
While this compound can influence the bioelectric properties of the respiratory mucosa, its direct effect on human bronchial ciliary activity in vitro appears to be weak and of short duration, suggesting it may not play a major role in mucociliary transport through this mechanism. karger.com
Interaction with Hypertonic Saline Therapy
Hypertonic saline (HS) inhalation is a widely used therapy in CF that works by creating an osmotic gradient to draw water onto the airway surface, thereby increasing ASL volume and improving mucus clearance. annualreviews.orgnih.govphysiology.org Interestingly, research has explored the interaction between this compound and hypertonic saline therapy in CF.
Some studies have shown that this compound can diminish the beneficial effects of hypertonic saline on sustained mucociliary clearance and pulmonary function in vivo. annualreviews.orgresearchgate.net This paradoxical observation suggests a complex interaction between the mechanisms of action of these two therapies. One proposed explanation is that this compound might inhibit aquaporin water channels, thereby negating the osmotic effect of hypertonic saline. researchgate.net However, other studies have argued against the inhibition of water channels as the primary mechanism for this compound's effect on hypertonic saline response. physiology.org
In vitro studies on human bronchial epithelial cells from CF donors have shown that exposure to hypertonic saline inhibits sodium current (INa), and the inclusion of this compound with HS led to an increased recovery of INa, paradoxically protecting the epithelium from the inhibitory effects of HS. physiology.orgphysiology.org This further highlights the intricate interplay between this compound and hypertonic saline at the cellular level.
Studies comparing hypertonic saline alone versus hypertonic saline with this compound have indicated that hypertonic saline alone was more effective in increasing mucociliary clearance. nih.gov
Acute Respiratory Distress Syndrome (ARDS) Research
Preclinical studies have investigated the potential of this compound in the context of Acute Respiratory Distress Syndrome (ARDS). ARDS is characterized by diffuse alveolar injury, including excessive inflammation, increased epithelial and vascular permeability, and alveolar edema. nih.gov While there is significant research into the pathogenesis of ARDS, effective pharmacotherapies remain limited, and treatment is primarily supportive. nih.gov
Research has explored the role of epithelial sodium channels (ENaC) in alveolar fluid clearance, a process often impaired in ARDS. This compound is known to inhibit ENaC. researchgate.netthieme-connect.com Studies involving mesenchymal stromal cells (MSCs) and their conditioned medium (CM) have shown therapeutic potential in ARDS models. researchgate.net The beneficial effects of MSC-CM on alveolar fluid clearance in endotoxin-injured lung models were significantly reduced when this compound was added to the medium, suggesting that the therapeutic effect is, in part, mediated by mechanisms sensitive to ENaC inhibition. researchgate.net Specifically, the addition of this compound (5 x 10-4 M) to MSC-CM reduced the therapeutic effect on alveolar fluid clearance by 56% in an ex vivo perfused lung model. researchgate.net This indicates that this compound's interaction with ENaC may influence the pathways involved in resolving pulmonary edema in ARDS.
Neurological and Psychiatric Disorder Research
This compound has been explored for its potential in neurological and psychiatric disorders, particularly due to its activity on acid-sensing ion channels (ASICs). ASICs are implicated in various neurological conditions, including anxiety. ukri.org
Neuroprotective Effects in Multiple Sclerosis Models
Neurodegeneration is a significant contributor to permanent disability in multiple sclerosis (MS). nih.govoup.com Current treatments primarily target inflammation but have shown less efficacy in preventing long-term disability. nih.govoup.com Targeting ASIC1, which is over-expressed in acute MS lesions and contributes to injurious intracellular ion accumulation, appears to be a potential strategy for limiting cellular injury and neurodegeneration. nih.govoup.com
This compound, as an ASIC1 inhibitor, has demonstrated neuroprotective and myeloprotective effects in experimental models of multiple sclerosis. nih.govoup.com These effects appear to occur independently of any significant anti-inflammatory influence. oup.com A translational study tested the neuroprotective effects of this compound in patients with primary progressive MS. nih.govoup.com This study assessed ASIC1 expression in chronic brain lesions and evaluated this compound's effect using MRI markers of neurodegeneration. nih.govoup.com Increased expression of ASIC1 was found in axons within chronic inactive lesions of progressive MS patients. nih.govoup.com Patients treated with this compound showed a significant reduction in the normalized annual rate of whole-brain volume loss compared to the pretreatment phase. nih.govoup.com Changes in diffusion indices of tissue damage in white and deep grey matter structures were also significantly reduced during the treatment phase. nih.govoup.com
This compound was also one of three drugs studied in the MS-SMART trial involving individuals with secondary progressive MS, although that trial did not find a clinical effect of the tested drugs. mstrust.org.ukmscanada.ca
Acid-Sensing Ion Channel (ASIC) Inhibition in Panic Disorder Research
Anxiety and panic disorders are common mental health conditions with a need for more effective treatments. ukri.orgnih.govresearchgate.netuoa.gr Acid-sensing ion channels (ASICs) in the brain have been associated with fear conditioning and anxiety responses, suggesting they could be therapeutic targets for panic disorder. ukri.orgnih.govresearchgate.netuoa.gr
This compound is an inhibitor of ASICs in the brain and has been shown to reduce panic symptoms in preclinical animal models. nih.govresearchgate.netuoa.grresearchgate.net Research suggests that ASIC inhibitors should have therapeutic potential in human anxiety. ukri.org Studies have explored the pharmacokinetics of intranasal this compound as a potential rapid-onset treatment for acute panic attacks. nih.govresearchgate.netuoa.grresearchgate.net Preclinical studies have shown that inhalation of this compound prevents panic symptoms in mice exposed to anxiogenic stimuli. researchgate.net
Oncology Research and Drug Repurposing
This compound and its derivatives have garnered attention as potential anti-cancer therapeutic agents, representing an area of drug repurposing. aacrjournals.orgresearchgate.netaacrjournals.orgscirp.orgrarecancernews.complos.orgbiorxiv.org Early studies linked their anti-tumor effects to the inhibition of sodium-proton antiporters and urokinase plasminogen activator. biorxiv.org More recent observations suggest that this compound derivatives exhibit selective cytotoxicity towards tumor cells compared to normal cells and can target therapy-resistant cancer cell populations. plos.orgbiorxiv.org
Anti-Myeloma Activity
This compound has demonstrated potent anti-myeloma activity in preclinical studies using myeloma cell lines and xenograft mouse models. aacrjournals.orgresearchgate.netaacrjournals.orgrarecancernews.comnih.govnih.govhealthtree.org Its activity has been observed in a broad panel of myeloma cell lines, regardless of TP53 status. researchgate.netnih.gov this compound also showed a synergistic effect when combined with other anti-myeloma drugs such as dexamethasone, melphalan, lenalidomide, and pomalidomide. aacrjournals.orgresearchgate.netaacrjournals.orgrarecancernews.comnih.govhealthtree.org
Beyond directly inducing cytotoxicity, this compound has been found to significantly alter the level of transcript isoforms and alternative splicing events, and deregulate the spliceosomal machinery in myeloma cells. aacrjournals.orgaacrjournals.orgrarecancernews.comnih.gov Disruption of the splicing machinery was associated with the inhibition of myeloma cell viability after this compound exposure. aacrjournals.orgaacrjournals.orgnih.gov
Induction of Apoptosis (Caspase-dependent and independent mechanisms)
A key mechanism by which this compound exerts its anti-myeloma activity is the induction of apoptosis. aacrjournals.orgresearchgate.netaacrjournals.orgnih.govnih.gov This apoptosis induction has been observed in various myeloma cell lines in a dose- and time-dependent manner. aacrjournals.orgresearchgate.net
Research indicates that the apoptosis induced by this compound in multiple myeloma cells is mediated by both caspase-dependent and caspase-independent mechanisms. aacrjournals.orgresearchgate.net Studies have shown significant activation of caspases 3/7, 8, and 9 in tested myeloma cell lines following this compound treatment. aacrjournals.org The involvement of a caspase-independent mechanism was also observed, as a pan-caspase inhibitor (Z-VAD-FMK) could inhibit caspase-3/7 activity but not the apoptosis induced by this compound. aacrjournals.org This dual mechanism of action contributes to this compound's cytotoxic effects on myeloma cells.
Data Table: this compound's Effects on Myeloma Cell Lines
Cell Line | Apoptosis Induction (24h) | Caspase 3/7 Activation | Caspase 8 Activation | Caspase 9 Activation | Mitochondrial Membrane Depolarization |
H929 | Significant (dose-dependent) aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Significant Decrease aacrjournals.org |
JJN3 | Significant (dose-dependent) aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Not specified in source |
KMS12-BM | Highest levels (dose-dependent) aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Significant Decrease aacrjournals.org |
MM1S | Significant (48h) aacrjournals.org | Not specified in source | Not specified in source | Not specified in source | Not specified in source |
U-266 | Significant (48h) aacrjournals.org | Not specified in source | Not specified in source | Not specified in source | Not specified in source |
RPMI-8226 | Significant (48h) aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Significant Activation aacrjournals.org | Significant Decrease aacrjournals.org |
Note: Data compiled from search result aacrjournals.org. Specific quantitative data for all metrics across all cell lines were not consistently available in the provided snippets.
Synergistic Effects with Chemotherapeutic Agents
Preclinical studies have indicated that this compound can exhibit synergistic effects when combined with certain chemotherapeutic agents. In the context of multiple myeloma, this compound demonstrated synergistic activity when used alongside dexamethasone, melphalan, lenalidomide, and pomalidomide. aacrjournals.orgrarecancernews.comaacrjournals.org This suggests that this compound could potentially enhance the efficacy of existing treatments for this hematological malignancy. Additionally, in canine osteosarcoma cells, this compound showed strong synergism with doxorubicin, leading to improved response compared to either agent alone. nih.gov This synergistic effect was associated with the activation of p53 signaling and downregulation of Akt phosphorylation, ultimately increasing apoptosis. nih.gov
Impact on Splicing Machinery and Gene Regulation
This compound has been found to modulate alternative splicing in various human cancer cells. aacrjournals.orgrarecancernews.com Alternative splicing is a crucial process that can be dysregulated in cancer, contributing to tumor progression and metastasis. aacrjournals.orgrarecancernews.com Studies have shown that this compound can alter the level of transcript isoforms and alternative splicing events, as well as deregulate the spliceosomal machinery. aacrjournals.orgaacrjournals.org This disruption of the splicing machinery has been linked to the inhibition of cancer cell viability. aacrjournals.orgaacrjournals.org For instance, in multiple myeloma cells, this compound treatment led to the modulation of the splicing machinery, observed through changes in the immunofluorescent staining of the SR protein SC35, which correlated with reduced cell viability. aacrjournals.org this compound has also been shown to "normalize" the splicing of certain oncogenic RNA transcripts, such as BCL-X, HIPK3, and RON/MISTR1, in human hepatocellular carcinoma cells. plos.orgresearchgate.netnih.gov This modulation of splicing is thought to be associated with the hypo-phosphorylation of splicing factors like SF2/ASF. plos.orgresearchgate.netnih.gov
Role of p53 Signaling
Research indicates a role for p53 signaling in the anticancer activity of this compound, particularly in multiple myeloma. Activation of p53 signaling has been observed in multiple myeloma cells with both wild-type and mutated TP53 after exposure to this compound. aacrjournals.orgrarecancernews.comaacrjournals.orgresearchgate.net This activation appears to contribute to this compound-induced apoptosis in cells expressing p53. aacrjournals.orgresearchgate.net However, this compound has also been shown to induce apoptosis in multiple myeloma cells lacking p53 expression, suggesting that mechanisms independent of p53 signaling are also involved in its antimyeloma effect. aacrjournals.orgrarecancernews.comaacrjournals.orgresearchgate.net In canine osteosarcoma cells, combination treatment with this compound and doxorubicin significantly upregulated p53-mitochondrial signaling, leading to increased apoptosis. nih.gov
Breast Cancer Research
This compound and its derivatives have attracted attention as potential therapeutic agents for breast cancer. biorxiv.orgresearchgate.net Early studies characterized amilorides as inhibitors of sodium-proton antiporter-dependent tumor growth and urokinase plasminogen activator-mediated metastasis. biorxiv.orgbiorxiv.org More recent observations suggest that this compound derivatives can be selectively cytotoxic towards tumor cells, including those resistant to conventional therapies. biorxiv.orgresearchgate.net
Lysosome-Dependent Cell Death Mechanisms
Recent studies highlight the induction of lysosome-dependent cell death (LDCD) as a mechanism by which this compound derivatives exert their cytotoxic effects in breast cancer cells, particularly in therapy-resistant populations. biorxiv.orgresearchgate.netbiorxiv.orgmdpi.com Lipophilic this compound derivatives, such as hexamethylene this compound (HMA) and LLC1, have been shown to induce lysosomal membrane permeabilization (LMP), a critical step preceding lysosome-dependent cell death. biorxiv.orgresearchgate.netbiorxiv.orgmdpi.comescholarship.orgnih.gov This process involves the release of lysosomal contents, such as cathepsins, into the cytosol, triggering cell death. biorxiv.orgmdpi.com Cancer cell lysosomes are considered particularly susceptible to LMP, providing a rationale for targeting lysosomes in cancer therapy. mdpi.com
Dual-Targeting Strategies (e.g., uPA and NHE1)
This compound's anticancer effects have been linked to its inhibitory activity against two distinct targets: urokinase-type plasminogen activator (uPA) and sodium-hydrogen exchanger isoform-1 (NHE1). researchgate.netmdpi.comnih.gov uPA is a serine protease involved in matrix degradation and tumor cell invasiveness, while NHE1 is a key regulator of transmembrane pH that supports carcinogenic progression. researchgate.netmdpi.comnih.gov this compound exhibits moderate inhibitory activity against both targets. researchgate.netmdpi.com Research is exploring the development of this compound derivatives with enhanced potency and selectivity, including compounds with dual-targeting activity against both uPA and NHE1, as well as those selective for a single target. mdpi.comnih.gov Inhibition of uPA by this compound has been shown to suppress the invasive capacity of human breast cancer cells. nih.govnih.gov Similarly, NHE1 inhibition has been investigated as a strategy to potentiate the effects of chemotherapy in breast cancer, including increasing sensitivity to doxorubicin and paclitaxel. nih.govresearchgate.net
Modulation of Cancer Cell pH
The tumor microenvironment is often characterized by extracellular acidity, which is known to contribute to cancer progression, including migration, invasion, and resistance to therapy. dovepress.comnih.gov Cancer cells maintain a relatively neutral to slightly alkaline intracellular pH by increasing the activity of proton extrusion mechanisms, such as the Na+/H+ exchanger isoform 1 (NHE1). dovepress.comnih.gov
This compound and its derivatives are known inhibitors of NHE1. nih.govnih.gov By inhibiting NHE1, this compound can interfere with the ability of cancer cells to extrude protons, potentially leading to intracellular acidification. dovepress.com This modulation of intracellular and extracellular pH can have several effects on cancer cells. Studies have shown that interfering with pH regulating systems is considered a potential therapeutic strategy in oncology. dovepress.commdpi.com
Preclinical studies have investigated the effects of this compound on cancer cell viability and pH in various cancer types, including prostate cancer. mdpi.com For instance, in vitro studies using PC3 prostate cancer cells demonstrated that this compound treatment could alter extracellular pH in a dose-dependent manner, moving the extracellular environment towards a more neutral pH value compared to control cells. mdpi.com
Data from studies on PC3 prostate cancer cells illustrate the dose-dependent effect of this compound on extracellular pH after 24 hours of treatment:
This compound Concentration (µM) | Extracellular pH |
Control | 6.8 |
400 | 6.89 |
800 | 6.97 |
This compound treatment has also been shown to induce a dose-dependent decrease in the viability of PC3 cells under normoxic conditions, with a more pronounced effect observed at higher concentrations and longer incubation times. mdpi.com While this compound's primary mechanism in this context is linked to NHE1 inhibition and subsequent pH modulation, it has also been shown to impede prostate cancer tumor growth by inhibiting urokinase-type plasminogen activator (uPA), an enzyme involved in cell migration and invasion. nih.gov Furthermore, this compound has demonstrated the ability to decrease the invasiveness of aggressive prostate cancer cells and reduce the size of prostate cancer xenografts in rodent models. nih.gov
Antiviral Research
This compound and its derivatives have been explored for their antiviral activities against a variety of viruses, including coronaviruses, flaviviruses, retroviruses, rhinoviruses, and coxsackieviruses. plos.orgnih.govresearchgate.net The antiviral mechanisms investigated include the inhibition of viral ion channels (viroporins), interference with viral RNA replication, and targeting of viral RNA structures.
Viroporins are small, virus-encoded transmembrane proteins that form ion channels or pores in cellular membranes, playing crucial roles in various stages of the viral life cycle, such as entry, assembly, and release. nih.govmdpi.comwhiterose.ac.uk this compound derivatives have been noted for their ability to inhibit ion channels formed by proteins from several virus families, including coronaviruses, flaviviruses, and retroviruses. plos.orgnih.govresearchgate.net
Hexamethylene this compound (HMA), a derivative of this compound, has been shown to inhibit the ion channel activity of the envelope (E) protein in coronaviruses and the Vpu protein in HIV-1. nih.govmdpi.commdpi.com The inhibition of these viral ion channels by this compound derivatives is considered a potential mechanism for their antiviral effects. nih.govmdpi.com
This compound and its derivatives have demonstrated antiviral effects against picornaviruses, a family that includes rhinoviruses and coxsackieviruses. plos.orgnih.gov Studies have shown that this compound and its derivative 5-(N-ethyl-N-isopropyl)this compound (EIPA) can inhibit the replication of coxsackievirus B3 (CVB3) in cell culture. nih.govresearchgate.netnih.govnih.govnih.govasm.org This inhibition of CVB3 replication appears to be a primary mechanism of their antiviral activity against this virus. nih.gov In contrast, while EIPA showed some inhibitory effect on the release of human rhinovirus 2 (HRV2), this compound and EIPA strongly inhibited CVB3 RNA replication but did not inhibit CVB3 release, suggesting different mechanisms of action between these picornaviruses. nih.gov
Research has also explored the potential of this compound-based small molecules to target conserved structured elements within viral RNA genomes. news-medical.netnih.govbiorxiv.orgfrontiersin.orgrutgers.edu This approach aims to interfere with essential viral processes like translation and replication by binding to specific RNA structures. news-medical.netbiorxiv.orgfrontiersin.org this compound has been described as a common RNA-binding scaffold. news-medical.net
Studies involving this compound-based small molecules have identified compounds that can potently inhibit the replication of certain coronaviruses by targeting RNA structures within the viral 5'-end. nih.govbiorxiv.orgrutgers.edu Nuclear magnetic resonance (NMR) studies have revealed specific interactions between amilorides and stem loops containing bulge-like structures in the viral RNA. nih.govbiorxiv.orgfrontiersin.org
This compound and its derivatives have been found to inhibit the activity of viral RNA-dependent RNA polymerases (RdRps), particularly in picornaviruses like coxsackievirus B3 (CVB3). researchgate.netnih.govnih.govasm.orgrmit.edu.au Studies have shown that this compound and EIPA inhibit the enzymatic activity of CVB3 3Dpol, the viral RNA polymerase, in vitro. researchgate.netnih.govnih.govrmit.edu.au This inhibition affects both VPg uridylylation and RNA elongation, crucial steps in viral RNA replication. researchgate.netnih.govrmit.edu.au
Further investigation into the mechanism of inhibition revealed that this compound acts as a competitive inhibitor of CVB3 3Dpol, competing with incoming nucleoside triphosphates (NTPs) and magnesium ions (Mg2+). researchgate.netnih.govasm.orgrmit.edu.au Docking analysis suggested a binding site for this compound within 3Dpol located near a Mg2+ ion and overlapping the nucleotide binding site, which supports the observed competitive inhibition. nih.govrmit.edu.au Resistance to this compound in CVB3 has been linked to specific amino acid substitutions in the 3Dpol enzyme. researchgate.netnih.govnih.govnih.govasm.org
Data illustrating the competitive inhibition of CVB3 3Dpol by this compound:
Inhibitor | Mechanism of Inhibition (vs. NTPs and Mg2+) | Affected Processes |
This compound | Competitive | VPg uridylylation, RNA elongation researchgate.netnih.govrmit.edu.au |
EIPA | Competitive | VPg uridylylation, RNA elongation researchgate.netnih.govrmit.edu.au |
Another study investigating the mechanism of this compound inhibition of CVB3 and poliovirus type 1 (PV1) RNA replication using membrane-associated RNA replication complexes showed that this compound inhibited viral RNA replication and VPgpUpU synthesis but did not affect polymerase elongation activity. ilo.org These findings suggested that this compound inhibited the initiation of RNA synthesis by inhibiting VPg uridylylation. ilo.org In silico binding studies supported this, showing that this compound docks in the VPg binding site on the viral RNA polymerase 3Dpol, potentially inhibiting VPg binding to 3Dpol. ilo.org
In the context of SARS-CoV-2, the causative agent of COVID-19, research has explored the potential of this compound and its derivatives as antiviral agents, particularly focusing on the viral envelope (E) protein. mdpi.comnih.govimmunologyresearchjournal.comnih.govfrontiersin.org The SARS-CoV-2 E protein is a small structural protein with ion channel activity that is involved in viral assembly, budding, and release. mdpi.comnih.govimmunologyresearchjournal.com
Studies have characterized the interactions of amilorides with the SARS-CoV-2 E protein. nih.govnih.gov The N-terminal region of the E protein has been identified as a principal binding site for this compound derivatives. nih.govnih.gov The binding affinity of this compound derivatives to the E protein has been shown to correlate with their antiviral potency against SARS-CoV-2 replication in cell culture. nih.govnih.gov For example, derivatives with bulkier hydrophobic groups at the 5' position of the pyrazine ring, such as HMA and EIPA, showed stronger binding to the E protein and more potent inhibition of viral replication compared to this compound. nih.govnih.gov
Mutations in the E protein, such as N15A, have been shown to affect the binding of this compound derivatives and alter virus-like particle production, suggesting a key role for specific residues in the interaction and antiviral activity. nih.govnih.gov These findings suggest that the SARS-CoV-2 E protein may be a target for the antiviral activity of this compound compounds. mdpi.comnih.gov
Anti-inflammatory and Immunomodulatory Research
This compound has been investigated for its ability to modulate inflammatory and immune responses. atsjournals.orgnih.gov Studies suggest it acts as a dual immunomodulator, capable of both reducing proinflammatory signals and augmenting anti-inflammatory responses in certain contexts. atsjournals.orgatsjournals.orgnih.gov
Blockade of Proinflammatory Cytokine Production (e.g., IL-1β, TNF-α, IL-6)
Research indicates that this compound can suppress the production of key proinflammatory cytokines. Exposure of alveolar epithelial cells to this compound or its analog, 5-(N,N-hexamethylene)-amiloride (HMA), reduced lipopolysaccharide (LPS)-induced secretion of interleukin (IL)-1β and tumor necrosis factor (TNF)-α in a dose-dependent manner. atsjournals.orgatsjournals.orgnih.gov This inhibitory effect was associated with the augmentation of a counter anti-inflammatory response. atsjournals.orgatsjournals.org this compound has also been shown to inhibit IL-8 and IL-6 release from respiratory syncytial virus (RSV)-infected airway epithelium. physiology.org In LPS-stimulated human THP-1 macrophages, this compound and benzamil decreased TNF, IL-6, IL-10, and IL-1β. physiology.orgresearchgate.net
The following table summarizes some findings on this compound's effect on proinflammatory cytokine production:
Cell Type / Model | Stimulus | Cytokine Inhibited | Key Finding | Source |
Alveolar epithelial cells | LPS | IL-1β, TNF-α | Reduced secretion in a dose-dependent manner. atsjournals.orgatsjournals.orgnih.gov | atsjournals.orgatsjournals.orgnih.gov |
RSV-infected airway epithelium | RSV | IL-8, IL-6 | Inhibited protein release. physiology.org | physiology.org |
LPS-stimulated human THP-1 macrophages | LPS | TNF, IL-6, IL-1β | Decreased levels. physiology.orgresearchgate.net | physiology.orgresearchgate.net |
A549 cells stimulated with IL-1 or TNF | IL-1, TNF | IL-8 | Inhibited IL-8 release. physiology.org | physiology.org |
Amplification of Anti-inflammatory Loop Responses (e.g., IL-6, IL-10)
In addition to blocking proinflammatory cytokines, this compound has been observed to amplify anti-inflammatory responses. In alveolar epithelial cells, the inhibitory effect of this compound on proinflammatory cytokines was associated with the augmentation of a counter anti-inflammatory response mediated by IL-6 and IL-10. atsjournals.orgatsjournals.orgnih.gov This suggests a dual role for this compound in modulating the inflammatory balance. atsjournals.orgatsjournals.org
Regulation of NF-κB Pathway
The nuclear factor-kappa B (NF-κB) pathway is a critical regulator of inflammatory responses. atsjournals.orgatsjournals.orgresearchgate.netwikipedia.orgresearchgate.net Analysis of the mechanism behind this compound's immunomodulatory effects has revealed the involvement of an inhibitory kappaB (IκB-α)/NF-κB-sensitive pathway. atsjournals.orgatsjournals.orgnih.gov this compound and its analog HMA suppressed the phosphorylation of IκB-α mediated by LPS, which allowed for its cytosolic accumulation. atsjournals.orgatsjournals.orgnih.gov Furthermore, both inhibitors interfered with the nuclear translocation of selective NF-κB subunits, an effect linked to the blockade of NF-κB DNA-binding activity. atsjournals.orgatsjournals.orgnih.gov This indicates that this compound can intervene with the nuclear translocation of selective NF-κB subunits, thereby blockading NF-κB activation. atsjournals.org
Role in Macrophage-Derived Cytokine Release
Macrophages play a significant role in the inflammatory response through the release of cytokines. nih.govresearchgate.net Studies suggest that epithelial Na+ channel (ENaC) activity may contribute to macrophage-derived cytokine release. physiology.orgresearchgate.net Inhibition of ENaC by this compound has been shown to reduce proinflammatory cytokines TNF and IL-6 in patients with type 2 diabetes and in THP-1-derived macrophages in vitro, potentially through a direct action on macrophages. physiology.orgresearchgate.net In LPS-stimulated human THP-1 macrophages, this compound and benzamil decreased TNF, IL-6, IL-10, and IL-1β. physiology.orgresearchgate.net
Inhibition of Viral RNA Polymerase
Anti-inflammatory and Immunomodulatory Research
This compound has been investigated for its capacity to influence inflammatory and immune system activities. atsjournals.orgnih.gov Studies suggest that it functions as a dual immunomodulator, capable of both suppressing proinflammatory signals and enhancing anti-inflammatory responses in specific contexts. atsjournals.orgatsjournals.orgnih.gov
Blockade of Proinflammatory Cytokine Production (e.g., IL-1β, TNF-α, IL-6)
Research indicates that this compound can reduce the production of key proinflammatory cytokines. In alveolar epithelial cells, exposure to this compound or its analog, HMA, led to a dose-dependent reduction in the secretion of LPS-induced IL-1β and TNF-α. atsjournals.orgatsjournals.orgnih.gov This inhibitory effect was observed in conjunction with the amplification of a counter anti-inflammatory response. atsjournals.orgatsjournals.org this compound has also been shown to inhibit the release of IL-8 and IL-6 from airway epithelium infected with RSV. physiology.org In studies using LPS-stimulated human THP-1 macrophages, this compound and benzamil were found to decrease levels of TNF, IL-6, IL-10, and IL-1β. physiology.orgresearchgate.net
The following table summarizes some findings on this compound's effect on proinflammatory cytokine production:
Cell Type / Model | Stimulus | Cytokine Inhibited | Key Finding | Source |
Alveolar epithelial cells | LPS | IL-1β, TNF-α | Reduced secretion in a dose-dependent manner. atsjournals.orgatsjournals.orgnih.gov | atsjournals.orgatsjournals.orgnih.gov |
RSV-infected airway epithelium | RSV | IL-8, IL-6 | Inhibited protein release. physiology.org | physiology.org |
LPS-stimulated human THP-1 macrophages | LPS | TNF, IL-6, IL-1β | Decreased levels. physiology.orgresearchgate.net | physiology.orgresearchgate.net |
A549 cells stimulated with IL-1 or TNF | IL-1, TNF | IL-8 | Inhibited IL-8 release. physiology.org | physiology.org |
Amplification of Anti-inflammatory Loop Responses (e.g., IL-6, IL-10)
Beyond its role in blocking proinflammatory cytokines, this compound has been noted to amplify anti-inflammatory responses. In alveolar epithelial cells, the reduction in proinflammatory cytokines by this compound was linked to the increased presence of an anti-inflammatory response mediated by IL-6 and IL-10. atsjournals.orgatsjournals.orgnih.gov This observation supports a dual function for this compound in influencing the balance of inflammation. atsjournals.orgatsjournals.org
Regulation of NF-κB Pathway
The NF-κB pathway is a key regulator in inflammatory processes. atsjournals.orgatsjournals.orgresearchgate.netwikipedia.orgresearchgate.net Investigations into the mechanism underlying this compound's immunomodulatory effects have pointed to the involvement of an IκB-α/NF-κB-sensitive pathway. atsjournals.orgatsjournals.orgnih.gov this compound and its analog HMA were found to suppress the LPS-mediated phosphorylation of IκB-α, leading to its accumulation in the cytosol. atsjournals.orgatsjournals.orgnih.gov Furthermore, both inhibitors interfered with the movement of specific NF-κB subunits into the nucleus, an effect associated with blocking the DNA-binding activity of NF-κB. atsjournals.orgatsjournals.orgnih.gov These findings suggest that this compound can disrupt the nuclear translocation of specific NF-κB subunits, thereby inhibiting NF-κB activation. atsjournals.org
Role in Macrophage-Derived Cytokine Release
Macrophages are significant contributors to the inflammatory response through the release of cytokines. nih.govresearchgate.net Studies propose that the activity of the epithelial Na+ channel (ENaC) may play a role in cytokine release from macrophages. physiology.orgresearchgate.net Blocking ENaC with this compound has been shown to decrease the levels of proinflammatory cytokines TNF and IL-6 in patients with type 2 diabetes and in THP-1-derived macrophages in vitro, potentially indicating a direct impact on these cells. physiology.orgresearchgate.net In LPS-stimulated human THP-1 macrophages, this compound and benzamil reduced the levels of TNF, IL-6, IL-10, and IL-1β. physiology.orgresearchgate.net
Other Emerging Research Areas
Osteoporosis Treatment Potential
While the provided outline includes osteoporosis treatment potential as an emerging research area for this compound, the search results did not yield specific information detailing this compound's role or potential in the treatment of osteoporosis. Therefore, content for this subsection cannot be provided based on the available search data.
Drug-Resistant Tuberculosis Research
Increasing antimicrobial resistance necessitates the identification of new therapeutic agents with novel or multiple molecular targets. researchgate.netnih.gov Energy conservation in Mycobacterium tuberculosis (Mtb), the bacterium responsible for tuberculosis, has been identified as a promising target for combating drug-resistant strains. researchgate.netnih.govufl.li
Research has shown that derivatives of this compound hold potential as anti-tubercular inhibitors. researchgate.netnih.gov Specifically, a 6-substituted derivative of this compound, known as HM2-16F, has demonstrated anti-tubercular activity comparable to bedaquiline, an FDA-approved drug used for drug-resistant tuberculosis. researchgate.netnih.govufl.li HM2-16F has also shown efficacy against bedaquiline-resistant mutants of Mtb. researchgate.netnih.govufl.li
The mechanism of action of HM2-16F involves interfering with bacterial energy conservation. researchgate.net Studies indicate that HM2-16F weakly inhibits the F1Fo-ATP synthase in Mtb, leading to ATP depletion. researchgate.netnih.govufl.li Additionally, it affects the entry of acetyl-CoA into the Krebs cycle. researchgate.netnih.govufl.li HM2-16F has also been shown to synergize with Q203 (Telacebec), a cytochrome bcc-aa3 oxidase inhibitor. researchgate.netnih.govufl.li Co-administration of HM2-16F and Q203 has been shown to sterilize in vitro cultures of Mtb within 14 days, with the synergy attributed to the direct inhibition of cytochrome bd oxidase by HM2-16F. researchgate.netnih.govufl.li These findings suggest that this compound derivatives could serve as a platform for discovering new drugs targeting energy generation in drug-resistant tuberculosis. researchgate.netnih.govufl.li
Thiazolidinediones-Induced Edema
Thiazolidinediones (TZDs), a class of drugs used to treat type 2 diabetes, are known to cause fluid retention and edema as a common side effect. vumc.orgnih.gov This fluid retention is a significant clinical limitation and can be particularly concerning for patients with or at high risk for heart failure. vumc.orgnih.govcore.ac.ukescholarship.org
Increasing evidence from animal models suggests that TZD-induced fluid retention is due to increased sodium retention in the distal nephron. core.ac.uk TZDs, which are agonists of peroxisome proliferator-activated receptor gamma (PPARγ), have been shown to stimulate sodium reabsorption in the distal nephron, potentially by upregulating the expression and translocation of ENaC. nih.govescholarship.orgnih.govpnas.org PPARγ is expressed in the renal cortical collecting duct, a region involved in regulating sodium and water balance via ENaC. nih.govpnas.org
Preclinical studies in mice have demonstrated that this compound, an ENaC blocker, can prevent the fluid retention and body weight gain induced by thiazolidinediones like pioglitazone. vumc.orgnih.govescholarship.org This suggests a potential role for this compound in counteracting the sodium retention caused by TZDs. vumc.orgnih.govcore.ac.ukescholarship.org Studies in human patients with type 2 diabetes who experienced rosiglitazone-induced fluid retention also showed that this compound was effective in arresting the continued plasma volume expansion. nih.gov These results support the hypothesis that ENaC upregulation plays a role in the pathophysiology of TZD-induced fluid retention. nih.gov
However, there can be discrepancies in findings between species and specific TZD compounds. For instance, one study in rats showed that post-treatment with this compound unexpectedly exacerbated fluid retention induced by farglitazar, highlighting the complexity of these interactions. nih.gov Despite this, the evidence from multiple studies, particularly those focusing on pioglitazone and rosiglitazone, supports the potential of this compound as a therapeutic strategy to mitigate TZD-induced fluid retention by targeting ENaC-mediated sodium reabsorption in the collecting duct. vumc.orgnih.govescholarship.orgnih.govpnas.org
Lithium-Induced Polyuria
Lithium is a medication used to treat affective disorders, but one of its major side effects is nephrogenic diabetes insipidus, characterized by polyuria (excessive urination). nih.govmedcraveonline.comopenaccessjournals.comnih.gov This occurs because lithium can inhibit vasopressin-mediated water reabsorption in the renal collecting tubules by interfering with the function and expression of aquaporin 2. medcraveonline.comopenaccessjournals.comnih.gov Lithium enters the renal principal cells primarily through the epithelial sodium channel (ENaC). medcraveonline.comopenaccessjournals.compsychiatrictimes.com
This compound, by blocking ENaC, can prevent the entry of lithium into these renal cells, thereby blunting lithium's inhibitory effect on water transport and reducing polyuria. medcraveonline.comopenaccessjournals.comnih.govpsychiatrictimes.com Preclinical studies in animals demonstrated that this compound could reduce lithium-induced polyuria without affecting lithium or potassium levels. nih.gov
Studies in patients with lithium-induced polyuria have shown that this compound administration leads to a decrease in urine volume and an increase in urine osmolality, indicating improved renal concentrating ability. nih.govnih.gov This reduction in urine output has been observed without significant changes in plasma lithium, potassium, or bicarbonate levels, or urinary excretion of sodium or lithium. nih.gov The effect of this compound in mitigating lithium-induced polyuria is attributed, at least in part, to its ability to block lithium entry into the collecting tubule cells via ENaC. medcraveonline.comopenaccessjournals.comnih.govpsychiatrictimes.com
This compound is often considered a preferred treatment option for lithium-induced polyuria compared to thiazide diuretics because it is less likely to increase serum lithium concentrations to potentially toxic levels and does not contribute to hypokalemia. openaccessjournals.compsychiatrictimes.comdroracle.ai
The mechanism by which this compound counteracts lithium's nephrotoxic effects is primarily the inhibition of ENaC in the principal cells of the nephron, which prevents lithium accumulation and the subsequent downregulation of Aquaporin 2 expression. medcraveonline.com This action helps to restore the kidney's ability to concentrate urine. nih.govmedcraveonline.comnih.gov
Here is a summary of the research findings discussed:
Research Area | Key Findings | Mechanism Involved |
Drug-Resistant Tuberculosis | This compound derivatives (e.g., HM2-16F) show anti-tubercular activity and efficacy against resistant strains. researchgate.netnih.govufl.li | Inhibition of bacterial F1Fo-ATP synthase and cytochrome bd oxidase. researchgate.netnih.govufl.li |
Thiazolidinediones-Induced Edema | This compound prevents/attenuates fluid retention induced by TZDs in animal models and human studies. vumc.orgnih.govescholarship.orgnih.gov | Blocking ENaC, counteracting TZD-induced upregulation of sodium reabsorption. nih.govescholarship.orgnih.govpnas.org |
Lithium-Induced Polyuria | This compound reduces polyuria and improves urine concentrating ability in lithium-treated patients and animal models. nih.govnih.gov | Blocking ENaC, preventing lithium entry into renal cells and its interference with water reabsorption. medcraveonline.comopenaccessjournals.comnih.govpsychiatrictimes.com |
Research Methodologies and Techniques Utilized in Amiloride Studies
In Vitro Experimental Models
In vitro models are fundamental to Amiloride research, allowing for controlled investigations of its effects on specific cell types and biological processes.
Cell Culture Systems
Cell culture systems are widely used to study the effects of this compound on various cell lines. These include investigations into its potential therapeutic applications and its interactions with ion channels and transporters.
Myeloma Cell Lines: this compound has demonstrated potent anti-myeloma activity in a broad panel of multiple myeloma (MM) cell lines. Studies have shown that this compound induces apoptosis in these cell lines. aacrjournals.orgresearchgate.net Furthermore, this compound has exhibited synergistic effects when combined with other therapeutic agents such as dexamethasone, melphalan, lenalidomide, and pomalidomide in MM cell lines. aacrjournals.orgresearchgate.net Research using myeloma cell lines has also investigated the mechanisms of action of this compound, including its impact on gene expression and splicing. aacrjournals.orgresearchgate.net Hexamethylene this compound (HA), a derivative of this compound, has also been shown to inhibit growth and induce apoptosis in MM cell lines, including those resistant to carfilzomib. d-nb.info
Breast Cancer Cell Lines: Breast cancer cell lines, such as T47D and MCF-7, have been used to study the effects of factors from polarized THP-1 macrophages on their cellular and functional changes, including the induction of a partial epithelial-mesenchymal transition (EMT) phenotype and increased migratory and invasive properties. oncotarget.com While these studies focus on macrophage influence on breast cancer cells, this compound's known inhibitory effects on Na+/H+ exchangers (NHEs), which are implicated in cancer progression, suggest that breast cancer cell lines could also be utilized to investigate this compound's direct or indirect impact on these processes. cdnsciencepub.com
Human Bronchial Epithelial Cells: Studies on human bronchial epithelial cells utilize techniques like ion-selective electrodes to measure ion transport. mdpi.com These cells possess various channels on their apical face, including the this compound-sensitive epithelial Na+ channel (ENaC). mdpi.com
THP-1 Macrophages: The human monocytic cell line THP-1 is commonly used to generate macrophages for in vitro studies, including those investigating the tumor microenvironment and the interaction between macrophages and cancer cells. nih.govnih.govresearchgate.net THP-1 cells can be differentiated into various macrophage populations, such as M0, M1, and M2, and co-cultured with cancer cells to evaluate cellular crosstalk. nih.govnih.govresearchgate.net While the provided search results primarily detail the use of THP-1 macrophages in the context of breast cancer cell interactions and not directly with this compound treatment, these cell systems represent a relevant model for future studies on how this compound or its analogs might influence macrophage function or their interaction with other cell types.
Ussing Chamber Electrophysiology
The Ussing chamber technique is a classical method used to measure ion transport across epithelial tissues or cultured cell monolayers. It allows for the measurement of transepithelial potential difference and short-circuit current, providing insights into the electrogenic transport of ions.
This compound is frequently used in Ussing chamber experiments as a specific blocker of epithelial sodium channels (ENaC) to isolate and study ENaC-mediated sodium transport. researchgate.netphysiology.orgfrontiersin.orgnih.gov For example, Ussing chamber studies on mucosal preparations of rat rectal colon showed that apical this compound inhibited a basal short-circuit current with an apparent half-inhibition constant (Ki) value of 0.20 μM. physiology.orgnih.gov In studies of human proximal tubule cells, Ussing chamber experiments demonstrated that this compound at a concentration of 10⁻⁴ M did not change the electrical properties, consistent with the known characteristics of proximal tubules. nih.gov The Ussing chamber is also used to study CFTR chloride current, where this compound is added to inhibit sodium transport at the apical side. researchgate.net
Ion-Selective Electrode Measurements
Ion-selective electrodes (ISEs) are electrochemical sensors used to measure the concentration or activity of specific ions in a solution. These electrodes generate a potential difference that is proportional to the logarithm of the ion activity.
ISEs have been developed and utilized for the determination of this compound itself, particularly in pharmaceutical samples. nahrainuniv.edu.iqnahrainuniv.edu.iqresearchgate.netscielo.br Studies have described the construction of this compound hydrochloride selective electrodes using polymeric membranes with different ion pairs and plasticizers. nahrainuniv.edu.iqresearchgate.net These electrodes exhibit characteristics such as slope, detection limit, and linear concentration range. nahrainuniv.edu.iqresearchgate.netscielo.br For instance, an this compound selective electrode based on salmon sperm ds-DNA as an ion pair, PVC matrix, and 2-nitrophenyl octylether (NPOE) as a plasticizer showed a Nernstian slope of 35.3 ± 1.0 mV decade⁻¹ and a detection limit of 1.5 × 10⁻⁶ mol L⁻¹. scielo.br
Here is a table summarizing some findings from this compound-selective electrode studies:
Electrode Composition (Ion Pair, Matrix, Plasticizer) | Slope (mV/decade) | Detection Limit (mol L⁻¹) | Linear Range (mol L⁻¹) | pH Range |
This compound-phosphotungstate, PVC, DBPH | - | - | - | - |
This compound-tetraphenylborate, PVC, DOP | - | - | - | - |
This compound-tetraphenylborate, PVC, TBP | - | - | - | - |
This compound-ds-DNA (salmon sperm), PVC, NPOE | 35.3 ± 1.0 | 1.5 × 10⁻⁶ | 1.6 × 10⁻⁶ to 1.0 × 10⁻² | 2.0 - 7.0 |
This compound-ds-DNA (calf thymus), PVC, NPOE | 12.0 ± 1.1 | - | - | - |
This compound, DOPP | 58.4 | 1.4 × 10⁻⁵ | - | 3.8 |
Amine- and this compound-ion, PVC, DBP | 40-56 | 2 × 10⁻⁵ (DBPH) | 1 × 10⁻⁴ to 1 × 10⁻¹ | - |
Note: Data for some parameters were not available in the provided snippets.
ISEs are also used in broader ion transport studies across epithelial cells, although detecting small changes in ion concentration can be technically challenging. mdpi.com
RNA-Seq, qRT-PCR, Immunoblotting, Immunofluorescence Assays
These molecular biology techniques are employed to investigate the effects of this compound on gene expression, protein levels, and cellular localization of specific molecules.
In studies of this compound's anti-myeloma activity, RNA-Seq, qRT-PCR, immunoblotting, and immunofluorescence assays were used to investigate its mechanisms of action. aacrjournals.orgresearchgate.net RNA-Seq experiments revealed that this compound significantly altered the level of transcript isoforms and alternative splicing events and deregulated the spliceosomal machinery. aacrjournals.orgresearchgate.net Immunofluorescence studies associated the disruption of the splicing machinery with the inhibition of myeloma cell viability after this compound exposure. aacrjournals.orgresearchgate.net Immunoblotting has also been used to examine the expression level of LAMP1, a marker of lysosomes, in cells treated with hexamethylene this compound (HA), an this compound derivative. d-nb.info Western blots have been used to characterize an this compound binding protein in adult alveolar type II pneumocytes using antibodies against epithelial Na+ channel proteins. nih.gov
Receptor Binding Profiling
Receptor binding profiling studies investigate the affinity and specificity of a compound for various receptors. This helps to understand the potential targets of a drug and its selectivity.
Studies have examined the receptor binding profiles of this compound and its analogues to investigate their interaction with different receptors, such as the adenosine-A₁ receptor. frontiersin.orgtandfonline.com These studies indicate that this compound and its analogues can affect radioligand binding to a variety of receptors, suggesting a widespread presence of an this compound binding site on receptors and other membrane proteins. tandfonline.com However, receptor binding profiles of this compound analogues have provided no evidence for a direct link between receptors and the Na+/H+ exchange, but rather indicate a common structure on receptor proteins. tandfonline.com An this compound binding protein with low affinity to benzamil and this compound has been characterized in adult alveolar type II pneumocytes. nih.gov
Molecular Docking and Computational Chemistry
Molecular docking and computational chemistry techniques are used to predict and analyze the binding interactions between this compound and its target molecules at an atomic level. These methods provide insights into binding sites, affinities, and the nature of interactions.
Molecular docking studies have been performed to investigate the interaction of this compound with various targets. This includes the interaction of this compound with the hASIC1a ion channel, using homology modeling of the pore region. worldscientific.com Docking results in this context agreed with the putative this compound binding site for alphaENaC channel chimeras. worldscientific.com Molecular docking has also been used to study the binding of this compound to human serum albumin (HSA), revealing that this compound primarily binds to Sudlow's site II, located in subdomain IIIA of HSA, with lesser affinity for Sudlow's site I. mdpi.com These studies utilize docking analysis to identify the location of binding and the residues involved in the interaction, such as van der Waals, hydrogen-bonding, and hydrophobic interactions. mdpi.com
Computational methods, including molecular docking and molecular dynamics simulations, have been employed to explore the potential inhibitory potency of this compound analogs against targets like the SARS-CoV-2 E viroporin. genominfo.org Docking simulations showed higher binding affinity scores for certain this compound analogs for SARS-CoV-2 E compared to SARS-CoV-1 E and indicated that these analogs engaged more amino acids in SARS-CoV-2 E. genominfo.org Molecular dynamics simulations further suggested that these ligands could alter the native structure and flexibility of the viral protein. genominfo.org Molecular docking has also been used to study the interaction of this compound with Acid-sensing ion channels (ASICs), showing that this compound interacts with specific amino acid residues. museu-goeldi.br Furthermore, molecular docking of modified this compound analogs has been used to study their binding properties to the NhaP-type cation-proton antiporter in Vibrio cholerae, revealing potential interactions with functionally important amino acid residues. cdnsciencepub.com
Here is a table summarizing some molecular docking findings for this compound:
Target | Binding Site(s) | Key Interacting Residues/Interactions | Notes |
hASIC1a ion channel | Pore region (putative alphaENaC binding site) | - | Results agree with putative ENaC binding site for this compound free base. worldscientific.com |
Human Serum Albumin (HSA) | Sudlow's site II (subdomain IIIA), Sudlow's site I (subdomain IIA) | Van der Waals, hydrogen-bonding, hydrophobic interactions | Primarily binds to site II with lesser affinity for site I. mdpi.com |
SARS-CoV-2 E viroporin | - | Engagement of amino acids | This compound analogs show higher binding affinity than for SARS-CoV-1 E. genominfo.org |
Acid-sensing ion channels (ASICs) | Binding pocket | GLU 412, LYS 373, GLU 374, GLN 277 (at pH 4.0) museu-goeldi.br | Interactions through conventional H-bonding and charged interactions. museu-goeldi.br |
Vibrio cholerae NhaP2 | Cytoplasmic side of TMS VI, extended chain of TMSs V and XII, loop between TMSs VIIII and IX | Functionally important amino acid residues | Blind docking approach used; analogs show promising binding. cdnsciencepub.com |
Note: Specific interacting residues may vary depending on the protein structure and simulation conditions used in different studies.
Computational chemistry, including Density Functional Theory (DFT) calculations, is also used to provide insights into the electronic and structural properties of this compound and its interactions with targets like ASICs. museu-goeldi.br
In Vivo Animal Models
Animal models play a crucial role in understanding the biological effects of this compound and its potential mechanisms of action in a living system before translation to human studies.
Xenograft Mouse Models (e.g., Multiple Myeloma)
Xenograft mouse models, where human cancer cells are implanted into immunocompromised mice, have been used to investigate the anti-tumor activity of this compound. In the context of multiple myeloma (MM), this compound has shown potent anti-myeloma activity in xenograft mouse models. nih.gov Studies have observed this compound-induced apoptosis in these models. nih.gov Furthermore, this compound demonstrated a synergistic effect when combined with other agents like dexamethasone and melphalan in MM cell lines and xenograft models. nih.gov Research using MM xenograft models has also explored the effects of this compound analogs, such as hexamethylene this compound (HA), which has demonstrated significant anti-MM effects in vivo by inducing lysosome-mediated cell death. researcher.life
Genetically Modified Animal Models (e.g., βENaC-overexpressing mice)
Genetically modified animal models are valuable for studying the specific roles of ion channels and transporters targeted by this compound. While the search results did not provide specific details on studies using βENaC-overexpressing mice and this compound oup.com, this compound is known to inhibit the epithelial sodium channel (ENaC), which consists of alpha, beta, and gamma subunits. Studies using genetically modified models focusing on sodium channel activity or related pathways would be relevant for understanding this compound's effects on sodium transport and its physiological consequences.
Ischemic-Reperfused Rat Hearts
Ischemic-reperfused rat hearts are a model used to study myocardial injury and the effects of interventions. This compound, as an inhibitor of the Na+/H+ exchanger (NHE), has been investigated in this model due to the role of sodium and calcium overload in ischemia-reperfusion injury. Studies have shown that inhibition of the Na+/H+ exchanger by this compound or its derivatives, such as dimethyl this compound, can improve ischemia/reperfusion-induced ionic disturbance and contractile failure in perfused rat hearts. ahajournals.org This suggests a role for this compound in mitigating the effects of sodium accumulation during ischemia. ahajournals.org
Clinical Study Designs
Clinical studies are essential for evaluating the efficacy and safety of this compound in human populations for various conditions.
Randomized Controlled Trials
Randomized controlled trials (RCTs) are considered the gold standard for evaluating interventions. This compound has been investigated in RCTs for several indications. For instance, a randomized, parallel, double-blinded, placebo-controlled trial (PREVER-prevention trial) investigated the effect of low-dose chlorthalidone in combination with low-dose this compound compared to placebo in patients with prehypertension. researchgate.net This trial demonstrated that the combination significantly reduced the incidence of hypertension and improved ECG-estimated left ventricular mass. researchgate.net
Another double-blind, placebo-controlled, crossover trial compared the effects of this compound and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. researchgate.net This study found that this compound had a numerically lower blood pressure-lowering effect than hydrochlorothiazide, but the differences were not statistically significant over the 4-week treatment period. researchgate.net The study also observed a statistically significant rise in 30-minute insulin levels with this compound treatment compared to other treatments. researchgate.net
This compound is also being investigated in clinical trials for its potential neuroprotective effects, such as the this compound Clinical Trial In Optic Neuritis (ACTION) protocol, a randomized, double-blind, placebo-controlled trial assessing this compound's efficacy in acute optic neuritis. This trial aims to assess neuroprotection using measures like retinal nerve fiber layer thickness and various brain MRI outcomes.
A double-blind randomized clinical trial also compared the blood pressure-lowering efficacy of this compound versus enalapril as add-on therapy in patients with uncontrolled blood pressure receiving hydrochlorothiazide.
Data Table: PREVER-Prevention Trial Findings researchgate.net
Outcome | Diuretic Group (Chlorthalidone + this compound) | Placebo Group | P-value |
Participants with Optimal BP | 25.6% | 19.3% | < 0.05 |
Mean Net SBP Reduction (mmHg) | 2.8 (95% CI 1.1 to 4.5) | - | - |
Mean Net DBP Reduction (mmHg) | 1.1 (95% CI 0.09 to 2.4) | - | - |
Double-Blind, Placebo-Controlled Studies
Double-blind, placebo-controlled studies are considered a robust method for evaluating the effects of a treatment by minimizing bias. In such studies involving this compound, neither the participants nor the researchers are aware of whether the participant is receiving this compound or a placebo.
One double-blind, placebo-controlled, crossover trial investigated the effects of this compound compared to hydrochlorothiazide on glucose tolerance in patients with essential hypertension. This study involved two parts, with one part including 37 patients who received, in random order, 4 weeks of treatment with hydrochlorothiazide, nebivolol, a combination of hydrochlorothiazide and nebivolol, this compound, and placebo, each separated by a 4-week placebo washout period. ahajournals.orgnih.gov The primary outcome measured was the difference in glucose levels during a 2-hour oral glucose tolerance test between the start and end of the 4-week treatment periods when comparing hydrochlorothiazide and this compound. nih.gov The study found that for similar blood pressure reductions, there were opposite changes in glucose levels between this compound and hydrochlorothiazide, with this compound showing no impairment of glucose tolerance compared to placebo. ahajournals.orgnih.gov
Another randomized, double-blind, placebo-controlled trial, the PREVER-Prevention trial, evaluated the effectiveness of a low-dose combination of chlorthalidone and this compound for the prevention of hypertension in patients with prehypertension. ahajournals.org This study included participants aged 30 to 70 with prehypertension who were randomized to receive either the combination pill or placebo after 3 months of lifestyle intervention. ahajournals.org The incidence of hypertension was significantly lower in the group receiving the chlorthalidone/Amiloride combination compared to the placebo group. ahajournals.org
A double-blind randomized crossover trial in patients over 60 with hypertension compared this compound plus hydrochlorothiazide, atenolol, the combination of all three, and placebo. All active treatments reduced blood pressure, with the combination being significantly superior. doi.org
Data from a double-blind, placebo-controlled, crossover trial examining the influence of this compound on exercise tolerance in healthy adults showed that this compound significantly increased time to failure and total work performed during blood-flow-restricted plantar flexion compared to placebo, without significantly influencing mean blood pressure or heart rate responses. nih.gov
The this compound Clinical Trial In Optic Neuritis (ACTION) is a phase II randomized, double-blind, placebo-controlled trial investigating the neuroprotective efficacy of this compound in patients with acute optic neuritis. researchgate.netnih.govbmj.com The primary objective is to assess neuroprotection by measuring peripapillary retinal nerve fiber layer thickness at 6 months in the affected eye compared to the unaffected eye at baseline. researchgate.netnih.gov
Here is a table summarizing findings from some double-blind, placebo-controlled studies involving this compound:
Study | Participants | Intervention | Key Finding Related to this compound | Citation |
Glucose Tolerance in Hypertension (Study 2) | 37 patients with essential hypertension | This compound vs. Hydrochlorothiazide vs. Placebo | This compound did not impair glucose tolerance, unlike hydrochlorothiazide. | ahajournals.orgnih.gov |
PREVER-Prevention Trial | Patients with prehypertension | Chlorthalidone/Amiloride combination vs. Placebo | Significantly lower incidence of hypertension with combination. | ahajournals.org |
Hypertension in Elderly Patients | 29 patients over 60 with hypertension | This compound + Hydrochlorothiazide vs. Placebo | Combination was effective in reducing blood pressure. | doi.org |
Exercise Tolerance in Healthy Adults | Healthy adults | This compound vs. Placebo | Increased exercise tolerance during blood-flow-restricted plantar flexion. | nih.gov |
ACTION Trial (Optic Neuritis) | 46 patients with acute optic neuritis | This compound vs. Placebo | Assessing neuroprotective efficacy (primary outcome: RNFL thickness). | researchgate.netnih.gov |
Prospective Observational Studies
Prospective observational studies involve observing groups of participants over time to see if a particular factor is associated with an outcome. While not providing the same level of evidence as randomized controlled trials regarding causality, they can offer valuable insights into the effects of this compound in real-world settings or specific patient cohorts.
One prospective study in 46 kidney transplant recipients (KTRs) investigated the effect of dietary sodium intake reduction on systolic blood pressure, emphasizing the potential contribution of sodium retention to posttransplant hypertension. physiology.org Although this study primarily focused on dietary intervention, it highlights the context of sodium balance, which is relevant to this compound's mechanism of action as an epithelial sodium channel blocker. physiology.org
Another prospective randomized clinical trial conducted in South Korea investigated whether this compound was noninferior to spironolactone in reducing home-measured systolic blood pressure in patients with resistant hypertension. medscape.com This study, while randomized, is described as prospective and observational in its design regarding the collection of data over time in the defined patient group. It included 118 patients with resistant hypertension and found that this compound was noninferior to spironolactone in lowering home systolic blood pressure after 12 weeks. medscape.combktimes.net
Subgroup Analyses in Patient Populations
Subgroup analyses involve examining the effects of a treatment within specific subsets of the study population. This can help identify if this compound has differential effects based on patient characteristics, genetic factors, or disease subtypes.
A substudy of the PATHWAY-2 trial assessed the effect of this compound in a subgroup of 146 participants with resistant hypertension during an optional open-label run-out phase. bktimes.net This analysis showed that this compound reduced clinic systolic blood pressure. bktimes.net
In a study focusing on black hypertensive individuals with the T594M polymorphism, an open, controlled study design was used to assess the effect of this compound. ahajournals.org In this subgroup of 14 individuals, this compound alone effectively controlled blood pressure to a level similar to that achieved with their usual multiple-drug regimens. ahajournals.org When this compound was withdrawn, there was a significant increase in blood pressure, suggesting a particular effectiveness in this genetic subgroup. ahajournals.org This observation supports the concept that the T594M polymorphism may affect sodium channel activity and that this compound may help reverse this abnormality. ahajournals.org
In the prospective randomized clinical trial comparing this compound and spironolactone for resistant hypertension, a subgroup analysis indicated that spironolactone was more effective in patients with evidence of aldosterone excess, while this compound showed efficacy regardless of these factors. jwatch.org
Future Directions and Emerging Research Avenues
Development of Novel Amiloride Analogues with Enhanced Specificity and Potency
Research continues into the synthesis and evaluation of novel this compound analogues aimed at improving specificity and potency for particular targets. This compound itself inhibits the epithelial sodium channel (ENaC) at submicromolar concentrations (≤1 μmol/L), but at higher concentrations, it can also inhibit other sodium transporters like the Na+/H+ exchanger (NHE) and the Na+/Ca2+ exchanger (NCX). The IC50 of this compound for NHE and NCX increases significantly with higher sodium concentrations, indicating decreased affinity.
Novel analogues are being developed to increase selectivity towards specific targets such as ENaC, NHE, or NCX. For instance, 6-(hetero)aryl-substituted this compound and 5-(N,N-hexamethylene)this compound (HMA) analogues have shown significantly higher potencies (up to 100-fold) against urokinase plasminogen activator (uPA), a potential anticancer target of this compound, while lacking diuretic effects. Studies evaluating the structure-property relationships of these analogues, including lipophilicity, solubility, and metabolic stability, are ongoing to identify candidates with improved profiles for potential therapeutic applications, such as in cancer metastasis. HMA, an this compound analog, has also shown stronger activity against Na+/H+ exchangers and better antifungal activity compared to this compound, with minimal inhibitory effects on ENaC.
Further Exploration of Drug Repurposing Potential
The potential to repurpose this compound for conditions beyond its traditional indications is an active area of investigation. Studies are exploring its use in conditions such as Attention Deficit Hyperactivity Disorder (ADHD) and bipolar disorder, particularly for managing side effects of other medications like lithium-induced kidney issues. This compound is also being investigated for its potential in treating multiple myeloma, with preclinical studies demonstrating its ability to induce apoptosis in myeloma cell lines and showing synergistic effects when combined with other agents like dexamethasone, melphalan, and lenalidomide.
Furthermore, multi-omics analyses and drug repurposing studies have suggested this compound as a potential candidate for osteoporosis treatment. Zebrafish experiments have indicated that this compound hydrochloride may have significant protective effects on osteoporosis induced by dexamethasone. Research is also exploring this compound derivatives as potential new agents for drug-resistant tuberculosis.
Mechanistic Research into Non-Canonical this compound Targets
While this compound is well-known for its ENaC inhibition, research is delving deeper into its effects on non-canonical targets. These include other ion channels and enzymes beyond ENaC. For example, this compound is known to block TRPP3, acid-sensing ion channels (ASIC), mechanogated membrane ion channels, and the Na+/H+ exchanger. It also inhibits urokinase-type plasminogen activator (uPA).
Studies are also investigating this compound's effects on calcium channels, particularly T-type calcium channels (CaV3 channels). Research indicates that this compound blocks CaV3.2 channels with higher affinity compared to CaV3.1 and CaV3.3 channels, suggesting a differential blocking mechanism. Further research aims to fully understand the canonical and non-canonical functions of CaV channels in diseases like cancer and the potential therapeutic benefits of calcium channel blockers like this compound in these contexts. This compound derivatives are also being explored for their activity against the mycobacterial F1Fo-ATP synthase, a potential target for drug-resistant tuberculosis.
Advanced Studies on this compound's Immunomodulatory Effects
Emerging research highlights the immunomodulatory potential of this compound. Studies have shown that this compound can influence both immune and non-immune cell functions and may exert anti-inflammatory effects by regulating the release of inflammatory mediators, including proinflammatory cytokines. Research in alveolar epithelial cells has demonstrated that this compound can blockade the production of proinflammatory cytokines like IL-1β and TNF-α while amplifying anti-inflammatory responses, such as IL-6 and IL-10. This biphasic regulation appears to be IL-10 sensitive and linked to targeting the IκB-α/NF-κB pathway, where this compound can suppress the phosphorylation of IκB-α, preventing the nuclear translocation of NF-κB subunits. This anti-inflammatory potential is being explored in the context of conditions like shock and respiratory syncytial virus (RSV) infection.
Investigation of this compound in Combination Therapies (excluding dosage/administration)
The use of this compound in combination with other therapeutic agents is being explored to enhance efficacy and potentially mitigate adverse effects. In the context of hypertension, this compound is often used with other diuretics like hydrochlorothiazide, and studies have shown that this combination can be superior to either drug alone in terms of blood pressure and glycemic effects. The combination of this compound and spironolactone has also been shown to lower systolic blood pressure in normotensive subjects, suggesting a complementary effect in inhibiting ENaC.
In oncology, this compound has shown synergistic effects when combined with standard multiple myeloma treatments such as dexamethasone, melphalan, and lenalidomide in preclinical studies. For cystic fibrosis, inhaled this compound is being studied in combination with hypertonic saline to assess improvements in mucociliary clearance. Inhaled this compound combined with tobramycin has also been investigated for eradicating Burkholderia cepacia complex in cystic fibrosis patients.
Refinement of Inhalation Therapies for Respiratory Diseases
Given this compound's mechanism of inhibiting ENaC, which is involved in regulating airway surface liquid, its potential as an inhaled therapy for respiratory diseases, particularly cystic fibrosis (CF), continues to be investigated. The hypothesis is that this compound therapy can decrease excessive sodium and water absorption in CF airway epithelium, thereby improving mucus rheology and clearance.
Early studies showed that inhaled this compound could increase mucus clearance in CF airways. However, initial clinical trials did not consistently demonstrate significant beneficial effects, potentially due to the drug's short half-life. Research is ongoing to develop this compound derivatives with longer half-lives for inhalation therapy. Furthermore, studies using animal models are exploring the timing of this compound intervention, suggesting that early initiation of therapy might yield more positive results in preventing lung disease progression. Refinements in formulation, such as nasal spray, are also being explored for potential uses in conditions like anxiety.
Pharmacogenomic and Personalized Medicine Approaches
Pharmacogenomics, the study of how genetic variations influence drug response, holds promise for optimizing this compound therapy. While specific pharmacogenomic studies directly on this compound are less extensively documented in the provided search results compared to other areas, the broader field of pharmacogenomics aims to tailor drug selection and dosing based on an individual's genetic makeup to enhance efficacy and minimize adverse effects.
Applying pharmacogenomic approaches to this compound could involve identifying genetic variants that influence the expression or function of its targets, such as ENaC or other ion channels and transporters it affects. This could help predict which patients are most likely to respond to this compound therapy or experience particular effects, potentially leading to more personalized treatment strategies, especially in conditions like hypertension or those where this compound is being repurposed. Mendelian Randomization analysis, for instance, has been used in drug repurposing studies involving this compound to assess the causal relationship between drug targets and disease outcomes based on genetic data.
Exploration of this compound's Role in Cellular Homeostasis Beyond Ion Transport
Beyond its canonical function as an ion channel blocker, particularly of ENaC, this compound and its derivatives are being investigated for their influence on various aspects of cellular homeostasis biorxiv.orgplos.orgnih.gov. These explorations delve into mechanisms that are not directly mediated by the primary ion transport pathways this compound is known to inhibit.
One area of focus is the potential for this compound derivatives to induce cell death, particularly in cancer cells biorxiv.orgplos.orgresearchgate.net. Studies suggest that certain this compound derivatives can exhibit selective cytotoxicity towards tumor cells compared to normal cells biorxiv.orgresearchgate.net. This cytotoxic effect may occur through mechanisms independent of ion channel inhibition, such as inducing lysosome-dependent cell death or programmed necrotic death biorxiv.orgplos.org. For instance, a novel lipophilic this compound derivative, LLC1, has been shown to induce lysosome-dependent cell death in therapy-resistant breast cancer cells biorxiv.org. Another derivative, UCD38B, a cell-permeant compound, has been observed to induce caspase-independent, AIF-mediated programmed necrotic death in breast cancer cells plos.org. These findings suggest that this compound derivatives can impact cellular viability through pathways distinct from their effects on ion transport, potentially involving lysosomal membrane permeabilization or the translocation of apoptosis-inducing factor (AIF) biorxiv.orgplos.org.
Furthermore, this compound has been shown to interact with other cellular targets, including the Na+/H+ exchanger (NHE) and Na+/Ca2+ exchanger (NCX), albeit with varying affinities compared to ENaC nih.govoup.com. While these interactions still involve ion transport systems, studies are exploring how their modulation by this compound might influence broader cellular functions like intracellular pH regulation, which is often dysregulated in diseases like cancer nih.govwikipedia.org. Cancer cells, for example, often exhibit higher intracellular pH compared to normal cells, and this compound's inhibition of NHE-1, which helps maintain normal intracellular pH, is being investigated in this context wikipedia.org.
Research also indicates that this compound can influence signaling pathways crucial for cellular processes such as differentiation. For example, this compound has been shown to inhibit osteoclastogenesis by suppressing the activity of nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs) spandidos-publications.com. This suggests a role for this compound in modulating intracellular signaling cascades that govern cell fate and function, independent of its immediate effects on ion flux across the plasma membrane spandidos-publications.com.
Emerging research also points to this compound's potential interactions with acid-sensing ion channels (ASICs) in the brain, suggesting a role in neurological and psychological conditions beyond ion homeostasis in the periphery nih.govnih.gov. Studies in preclinical models have explored the use of inhaled this compound as a potential anxiolytic agent by targeting ASICs nih.govnih.gov. This highlights a potential influence on neuronal activity and related behaviors through mechanisms involving these specific ion channels, which are distinct from ENaC.
These diverse findings collectively emphasize that the biological activity of this compound extends beyond its well-characterized effects on renal sodium channels. Future research is needed to fully elucidate the complex interactions of this compound and its derivatives with various cellular components and signaling pathways, which could uncover novel therapeutic applications.
Addressing Challenges in Clinical Translation and Bridging Preclinical-Clinical Gaps
Despite the promising preclinical findings for this compound and its derivatives in various disease models, significant challenges remain in translating these observations into successful clinical applications biorxiv.orgresearchgate.net. Bridging the gap between preclinical research and clinical implementation requires addressing several key hurdles.
One major challenge is the modest cytotoxic potency of this compound and many of its derivatives, often requiring high micromolar to low millimolar concentrations to achieve significant effects in vitro biorxiv.orgresearchgate.net. This limited potency can pose challenges for achieving therapeutic concentrations in target tissues in vivo without causing off-target effects or toxicity. Structure-activity relationship studies are ongoing to develop novel this compound derivatives with enhanced potency and selectivity for specific cellular targets or disease states biorxiv.orgnih.gov. For instance, modifications at the C(5) position of the this compound pharmacophore have shown promise in enhancing cytotoxicity towards cancer cells biorxiv.orgresearchgate.net.
Another critical aspect is the pharmacokinetic profile of this compound and its derivatives. Poor pharmacokinetic properties, such as limited cell permeability or unfavorable metabolism, can hinder their effectiveness in vivo biorxiv.org. For example, while some this compound derivatives show potent effects in vitro, their translation is hampered by poor pharmacokinetic properties in animal models biorxiv.org. Research into developing cell-permeant derivatives, as demonstrated with UCD38B, is crucial for improving intracellular delivery and efficacy plos.org. Exploring alternative routes of administration, such as intranasal delivery for targeting the brain, is also being investigated to improve pharmacokinetic profiles and target engagement for specific indications nih.govresearchgate.net.
Bridging the preclinical-clinical gap also necessitates a deeper understanding of the specific mechanisms of action relevant to the disease being targeted. While this compound's effects on ion channels are well-understood in the context of its diuretic use, its mechanisms in other conditions, such as cancer or neurological disorders, may involve different targets or pathways biorxiv.orgplos.orgwikipedia.orgnih.govnih.gov. Clearly defining these mechanisms in preclinical studies is essential for designing rational clinical trials and identifying appropriate patient populations.
Furthermore, the complexity of biological systems and the potential for off-target effects of this compound and its derivatives require careful consideration. While preclinical studies may show promising results in simplified models, the in vivo environment is far more intricate. Understanding how this compound interacts with various cell types, tissues, and physiological processes is crucial for predicting its effects in humans. Clinical trials, such as those investigating this compound for neuroprotection in multiple sclerosis, have sometimes yielded disappointing results despite promising preclinical data, highlighting the challenges in translating findings from one context to another mssociety.org.uk.
Rigorous and well-designed clinical trials are essential to validate preclinical findings and assess the efficacy and safety of this compound and its derivatives for new indications nih.govstatpearls.com. These trials need to carefully consider factors such as optimal dosing, patient selection, and appropriate endpoints based on the proposed mechanism of action. The need for randomized controlled trials to validate preclinical findings in areas like the use of this compound in certain kidney conditions has been highlighted nih.govstatpearls.com.
Q & A
Q. What are the primary molecular targets of amiloride, and how do these interactions influence experimental design in sodium transport studies?
this compound primarily inhibits epithelial sodium channels (ENaC) and acid-sensing ion channel-1 (ASIC-1), which are critical in sodium homeostasis and cellular signaling. Methodologically, researchers often use in vitro electrophysiology (e.g., whole-cell patch clamp) to quantify this compound’s inhibitory effects on ion currents . For ENaC studies, experimental designs should account for tissue-specific expression (e.g., renal vs. airway epithelia) and validate target specificity using competitive antagonists or knockout models .
Q. How can researchers standardize this compound solution preparation to address solubility challenges in physiological studies?
this compound’s limited solubility in isotonic solutions (e.g., 0.3% NaCl) necessitates careful preparation. A common protocol involves preparing a 10 mmol/L stock at pH 6.4, stored in dark glass vials at room temperature to prevent flocculation. If precipitation occurs, warming the solution to 50°C and manual agitation can restore homogeneity. Researchers must report osmolality (e.g., 116 mOsm for 10 mmol/L this compound vs. 303 mOsm for frusemide) and validate stability via UV spectrophotometry or LC-MS .
Q. What statistical approaches are recommended for analyzing this compound’s dose-response effects in airway resistance studies?
Repeated-measures ANOVA is suitable for comparing pre- and post-treatment outcomes (e.g., FEV1 changes). For dose-response curves, non-linear regression models (e.g., log[inhibitor] vs. response) should include 95% confidence intervals. In studies with heterogeneous responses (e.g., "LOW" vs. "HIGH" this compound responders), cluster analysis or stratification by baseline parameters (e.g., sodium intake) can reduce variability .
Advanced Research Questions
Q. How can computational docking studies guide the design of this compound analogs with enhanced specificity for ASIC-1?
Molecular docking software (e.g., AutoDock Vina) predicts binding affinities between this compound and ASIC-1’s extracellular domains. Researchers should prioritize analogs with lower free energy scores (ΔG < -7 kcal/mol) and validate predictions via electrophysiology. For example, substituting the guanidinium group with hydrophobic moieties may improve potency. Post-docking, mutagenesis of predicted interaction sites (e.g., residue 299 in CVB3 polymerase) can confirm mechanistic relevance .
Q. What methodologies resolve conflicting data on this compound’s role in tumor microenvironment modulation?
Discrepancies in MMP3/MMP9 inhibition (e.g., reduced activity in lung tumors vs. no effect in glioblastoma) may arise from pH-dependent drug stability. Multivariate curve resolution alternating least squares (MCR-ALS) can deconvolute photodegradation products under varying pH (4.0–9.0) and irradiation conditions. Complementary LC-MS identifies degradation byproducts (e.g., hydroxylated derivatives), ensuring observed effects are drug-specific rather than artifact-driven .
Q. How does this compound synergize with existing therapies in relapsed multiple myeloma, and what experimental models validate this?
In xenograft models, this compound (5–20 mg/kg daily) synergizes with dexamethasone by disrupting spliceosomal machinery (e.g., downregulating SF3B1). RNA-Seq and isoform-level analysis (e.g., Cufflinks) quantify alternative splicing events. Mechanistic validation requires immunofluorescence for nuclear speckle disassembly and p53 pathway activation via immunoblotting (e.g., phospho-p53 Ser15). Studies must include TP53-mutant cell lines to assess resistance mechanisms .
Methodological Considerations
Q. How should researchers address variability in this compound responses across epithelial tissues?
Stratify samples by transporter expression (e.g., Ussing chamber measurements of trans-epithelial resistance). For airway studies, differentiate between apical vs. basolateral ENaC activity using polarized cell cultures. In renal research, urinary this compound concentration assays (via HPLC) correlate pharmacokinetics with sodium excretion .
Q. What analytical frameworks are optimal for studying this compound’s pH-dependent photodegradation in drug formulation research?
Combine kinetic and acid-base titration data via MCR-ALS with hard modeling constraints. Equilibrium constraints resolve acid-base species (e.g., protonated vs. deprotonated this compound), while kinetic constraints model degradation pathways. Rate constants (k) estimated via Arrhenius plots at 25–45°C inform storage guidelines .
Retrosynthesis Analysis
AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.
One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.
Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.
Strategy Settings
Precursor scoring | Relevance Heuristic |
---|---|
Min. plausibility | 0.01 |
Model | Template_relevance |
Template Set | Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis |
Top-N result to add to graph | 6 |
Feasible Synthetic Routes
Featured Recommendations
Most viewed | ||
---|---|---|
Most popular with customers |
Disclaimer and Information on In-Vitro Research Products
Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term "in glass," involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.